FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
(See section 10, rule 13)
“NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING
SAME”
KOWA COMPANY, LTD., of 6-29, Nishiki 3-chome, Naka-ku, Nagoya-shi, Aichi
4608625, Japan
The following specification particularly describes the invention and the manner in which
it is to be performed.
2
TECHNICAL FIELD
[0001]
The present invention relates to novel phenylpyridine
derivatives that have both angiotensin II antagonistic activity
and a PPAR activation effect, and a pharmaceutical agent
containing the same.
BACKGROUND ART
[0002]
In recent years, diseases such as diabetes, hypertension,
dyslipidemia and obesity which can be a risk factor for
arteriosclerotic diseases have been rapidly increasing due to
changes in life style with improvements in living standard, i.e.,
high calorie and high cholesterol type diet, obesity, lack of
exercise, aging, and the like. It is known that, although being
a risk factor independent of each other, overlap of the diseases
can cause an occurrence of arteriosclerotic diseases at higher
frequency or aggravation of the diseases. As such, with the
understanding of a condition having a plurality of risk factors
for arteriosclerotic diseases as metabolic syndrome, efforts
have been made to elucidate the cause of the syndrome and to
develop a therapeutic method therefor.
[0003]
Angiotensin II (herein below, also abbreviated as “AII”)
is a peptide that is found to be an intrinsic pressor substance
produced by renin-angiotensin system (i.e., RA system). It is
3
believed that pharmacological inhibition of angiotensin II
activity can lead to treatment or prevention of circulatory
diseases such as hypertension. Accordingly, an inhibitor for
angiotensin converting enzyme (ACE) which inhibits the enzyme
for promoting the conversion of angiotensin I (AI) to
angiotensin II has been clinically used as an inhibitory agent
for RA system. Furthermore, an orally administrable AII
receptor blocker (Angiotensin Receptor Blocker: ARB) has been
developed, and losartan, candesartan, telmisartan, valsartan,
olmesartan, irbesartan, and the like are already clinically
used as a hypotensive agent. It is reported by many clinical
or basic studies that, as having not only a hypotensive activity
but also other various activities including an
anti-inflammatory activity, an endothelial function improving
activity, a cardiovascular remodeling inhibiting activity, an
oxidation stress inhibiting activity, a proliferation factor
inhibiting activity, insulin resistance improving activity,
and the like, ARB is useful for cardiovascular diseases, renal
diseases, arteriosclerosis, and the like (Non-Patent Documents
1 and 2). Most recently, it is also reported that ARB
particularly has a kidney protecting activity which does not
depend on a hypotensive activity (Non-Patent Document 3).
[0004]
Meanwhile, three isoforms, i.e., ,  and  have been
identified so far for peroxisome proliferator-activated
receptors (PPARs) which belong to a nuclear receptor
superfamily. Among them, PPAR is an isoform most abundantly
4
expressed in an adipose tissue and it plays an important role
in differentiation of adipocytes or metabolism of glycolipids.
Currently, thiazolidinedione derivatives (i.e., TZD) such as
pioglitazone or rosiglitazone are clinically used as a
therapeutic agent for diabetes having a PPAR activation effect,
and they are known to have an activity of improving insulin
resistance, glucose tolerance, lipid metabolism, and the like.
Further, it is recently reported that, based on activation of
PPAR, TZD exhibits various activities including a hypotensive
activity, an anti-inflammatory activity, an endothelial
function improving activity, a proliferation factor inhibiting
activity, an activity of interfering RA system, and the like.
It is also reported that, according to such multiple activities,
TZD shows a kidney protecting activity particularly in diabetic
nephropathy without depending on blood sugar control
(Non-Patent Documents 4, 5, 6, 7, and 8). Meanwhile, there is
also a concern regarding adverse effects of TZD caused by PPAR
activation, such as body fluid accumulation, body weight gain,
peripheral edema, and pulmonary edema (Non-Patent Documents 9
and 10).
[0005]
It has been recently reported that telmisartan has a PPAR
activation effect (Non-Patent Document 11). It has been also
reported that the irbesartan has the same activity (Non-Patent
Document 12). These compounds have both an RA system inhibiting
activity and a PPAR activation effect, and thus are expected
to be used as an integrated agent for prevention and/or
5
treatment of circulatory diseases (e.g., hypertension, heart
disease, angina pectoris, cerebral vascular disorder, cerebral
circulatory disorder, ischemic peripheral circulatory
disorder, kidney disease, and the like) or diabetes-related
diseases (e.g., type 2 diabetes mellitus, diabetic complication,
insulin resistant syndrome, metabolic syndrome,
hyperinsulinemia, and the like) without increasing a risk of
body fluid accumulation, body weight gain, peripheral edema,
pulmonary edema, or congestive heart failure that are concerned
over the use of TZD (Patent Document 1). Among them, for
diabetic nephropathy, a synergistic prophylactic and/or
therapeutic effect is expected from composite kidney protecting
activity that is based on activities of RA system inhibition
and PPAR activation.
[0006]
As a compound having the activities above, pyrimidine and
triazine derivatives (Patent Document 1), imidazopyridine
derivatives (Patent Document 2), indole derivatives (Patent
Document 3), imidazole derivatives (Patent Document 4), and
condensed ring derivatives (Patent Document 5) have been
reported. However, there is no description or suggestion
regarding the phenylpyridine derivatives of the present
invention.
Meanwhile, Patent Document 6 discloses a compound
represented by the following formula (A):
[0007]
[Chemical Formula 1]
6
[0008]
[in the formula, R1 is an optionally substituted
hydrocarbon residue which is optionally bonded through a hetero
atom, R2 is an optionally substituted 5 to 7 membered
heterocyclic residue having, as a group capable of constituting
the ring, a carbonyl group, a thiocarbonyl group, an optionally
oxidized sulfur atom or a group convertible into them, X is a
direct bond or bonding via a spacer having an atomic length of
two or less between the ring Y and the ring W, W and Y are an
optionally substituted aromatic hydrocarbon residue
optionally containing a hetero atom or an optionally
substituted heterocyclic residue; n is an integer of 1 or 2,
a and b forming the heterocyclic residue are independently one
or two optionally substituted carbon or hetero atoms, c is an
optionally substituted carbon or hetero atom, and, in the group
of the formula,
[0009]
[Chemical Formula 2]
[0010]
7
substituent groups on adjacent two atoms forming the ring
are optionally bonded to each other to form a 5 to 6 membered
ring together with the two atoms forming the ring]. As a
preferred W-Y ring system, biphenyl is exemplified. In the
Examples, only the biphenyl derivatives are specifically
described. The compounds disclosed in Patent Document 6 are
different from the compounds of the present invention in terms
of the ring bonded to the pyridinyl methyl group. In addition,
Patent Document 6 includes no descriptions or suggestions
relating to a PPAR activation effect as a pharmacological
activity or treatment of diabetes, obesity, or metabolic
syndromes.
PRIOR ART DOCUMENT
PATENT DOCUMENT
[0011]
Patent Document 1: WO 2008/062905 A
Patent Document 2: WO 2008/084303 A
Patent Document 3: WO 2008/096820 A
Patent Document 4: WO 2008/096829 A
Patent Document 5: WO 2008/143262 A
Patent Document 6: JP 5-271228 A
NON-PATENT DOCUMENT
[0012]
Non-Patent Document 1: AMER. J. Hypertension, 18, 720
(2005)
Non-Patent Document 2: Current Hypertension Report, 10,
8
261 (2008)
Non-Patent Document 3: Diabetes Care, 30, 1581 (2007)
Non-Patent Document 4: Kidney Int., 70, 1223 (2006)
Non-Patent Document 5: Circulation, 108, 2941 (2003)
Non-Patent Document 6: Best Pract. Res. Clin. Endocrinol.
Metab., 21 (4), 687 (2007)
Non-Patent Document 7: Diab. Vasc. Dis. Res., 1 (2), 76
(2004)
Non-Patent Document 8: Diab. Vasc. Dis. Res., 2 (2), 61
(2005)
Non-Patent Document 9: J. Clin. Invest., 116 (3), 581
(2006)
Non-Patent Document 10: FASEB J., 20 (8), 1203 (2006)
Non-Patent Document 11: Hypertension, 43, 993 (2004)
Non-Patent Document 12: Circulation, 109, 2054 (2004)
SUMMARY OF THE INVENTION
PROBLEMS TO BE SOLVED BY THE INVENTION
[0013]
An object of the invention is to provide a novel compound
that is useful as a pharmaceutical agent for preventing and/or
treating hypertension as a circulatory disease, diabetes as a
metabolic disease, and the like, and a pharmaceutical
composition using the novel compound.
MEANS FOR SOLVING THE PROBLEMS
[0014]
9
As a result of intensive studies to achieve the purpose
described above, the inventors found that the compound
represented by the formula (I) below has both an excellent
angiotensin II antagonistic activity and an excellent PPAR
activation effect, and therefore completed the invention.
[0015]
Specifically, the present invention relates to the
following inventions.
[1] A compound represented by the formula (I) below or
a salt thereof, or a solvate thereof:
[0016]
[Chemical Formula 3]
[0017]
[in the formula, ring A represents the following formula
(II) or formula (III):
[0018]
[Chemical Formula 4]
10
[0019]
ring B represents the following formula (IV) or formula
(V):
[0020]
[Chemical Formula 5]
[0021]
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
[0022]
[2] The compound described in the above [1] or a salt
11
thereof, or a solvate thereof, in which the ring A in the formula
(I) is the formula (II) described above, and X is a nitrogen
atom.
[3] The compound described in the above [1] or [2] or a
salt thereof, or a solvate thereof, in which the ring B in the
formula (I) is the formula (V) described above.
[4] The compound described in any one of the above [1]
to [3] or a salt thereof, or a solvate thereof, in which R2 in
the formula (I) is a branched C3-6 alkyl group or a C3-8 cycloalkyl
group.
[5] The compound described in any one of the above [1]
to [4] or a salt thereof, or a solvate thereof, in which R1 in
the formula (I) is a C1-3 alkyl group or a C5-6 alkyl group.
[6] The compound described in any one of the above [1]
to [5] or a salt thereof, or a solvate thereof, in which the
ring A in the formula (I) is the formula (II) described above
and the ring B is the formula (V) described above.
[7] The compound described in any one of the above [1]
to [6] or a salt thereof, or a solvate thereof, in which X in
the formula (I) is a nitrogen atom and R3 and R4 are each
independently a hydrogen atom, a halogen atom, a C1-6 alkyl group,
a halo C1-6 alkyl group, or a C1-6 alkoxy group.
[8] The compound described in the above [7] or a salt
thereof, or a solvate thereof, in which R3 and R4 in the formula
(I) are each independently a hydrogen atom or a C1-6 alkoxy group.
[0023]
[9] The compound described in the above [1] or a salt
12
thereof, or a solvate thereof, in which the compound represented
by the formula (I) is a compound selected from a group consisting
of:
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-ethyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-ethylpyrimidin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-isopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-isopropylpyrimidin-4(3H)-o
ne,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H
)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
13
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopentyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclohexyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylthio)ethoxy]pyrimidin-2-yl}pyri
midin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}
pyrimidin-4(3H)-one,
3-{2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihyd
ropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-oxadiazo
l-5(4H)-one,
3-{2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-
oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one,
14
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)
-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
15
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrim
idin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2
-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylsulfonyl)ethoxy]p
yrimidin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyrid
in-2-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-2-methyl-3-(pyridin-2-yl)pyrimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-methoxypyridin-2-yl)-2-methylpyrimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylpy
rimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(4,6-dimethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)
-one,
3-{2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one,
3-{2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one,
16
3-{2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one,
3-{2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one.
[0024]
[10] The compound described in the above [1] or a salt
thereof, or a solvate thereof, in which the compound represented
17
by the formula (I) is a compound selected from a group consisting
of:
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-isopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-isopropylpyrimidin-4(3H)-o
ne,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H
)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopentyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclohexyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
3-{2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-
18
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)
-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
19
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one.
[0025]
[11] The compound described in the above [1] or a salt
thereof, or a solvate thereof, in which the compound represented
by the formula (I) is a compound selected from a group consisting
of:
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
20
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one.
Meanwhile, the alkyl group such as butyl in the
nomenclature of the above-mentioned compounds represents a
straight (normal) chain unless particularly described.
[0026]
[12] A pharmaceutical composition containing the
compound described in any one of the above [1] to [11] or a salt
thereof, or a solvate thereof, and a pharmaceutically
acceptable carrier.
[13] The pharmaceutical composition described in the
above [12], in which the ring A in the formula (I) is the formula
(II) described above and X is a nitrogen atom.
[14] The pharmaceutical composition described in the
above [12] or [13], in which the ring B in the formula (I) is
the formula (V) described above.
[15] The pharmaceutical composition described in any one
of the above [12] to [14], in which R2 in the formula (I) is
a branched C3-6 alkyl group or a C3-8 cycloalkyl group.
[16] The pharmaceutical composition described in any one
of the above [12] to [15], in which R1 in the formula (I) is
a C1-3 alkyl group or a C5-6 alkyl group.
21
[17] The pharmaceutical composition described in any one
of the above [12] to [16], in which the ring A in the formula
(I) is the formula (II) described above and the ring B is the
formula (V) described above.
[18] The pharmaceutical composition described in any one
of the above [12] to [17], in which X in the formula (I) is a
nitrogen atom and R3 and R4 are each independently a hydrogen
atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group,
or a C1-6 alkoxy group.
[19] The pharmaceutical composition described in the
above [18], in which R3 and R4 in the formula (I) are each
independently a hydrogen atom or a C1-6 alkoxy group.
[20] The pharmaceutical composition described in any one
of the above [12] to [19], having both angiotensin II receptor
antagonistic activity and a PPAR activation effect.
[0027]
[21] The pharmaceutical composition described in any one
of the above [12] to [20], which is an agent for preventing and/or
treating a circulatory disease.
[22] The pharmaceutical composition described in the
above [21], in which the circulatory disease is hypertension,
heart disease, angina pectoris, cerebral vascular disorder,
cerebral circulatory disorder, ischemic peripheral
circulatory disorder, kidney disease, or arteriosclerosis.
[23] The pharmaceutical composition described in any one
of the above [12] to [20], which is an agent for preventing and/or
treating a metabolic disease.
22
[24] The pharmaceutical composition described in the
above [23], in which the metabolic disease is type 2 diabetes
mellitus, diabetic complication (diabetic retinopathy,
diabetic neuropathy, or diabetic nephropathy), insulin
resistant syndrome, metabolic syndrome, or hyperinsulinemia.
[25] A method of preventing and/or treating a circulatory
disease, the method including administering an effective amount
of the compound described in any one of the above [1] to [11]
or a salt thereof, or a solvate thereof to a patient who is in
need of the treatment.
[26] The method described in the above [25], in which the
circulatory disease is hypertension, heart disease, angina
pectoris, cerebral vascular disorder, cerebral circulatory
disorder, ischemic peripheral circulatory disorder, kidney
disease, or arteriosclerosis.
[27] A method of preventing and/or treating a metabolic
disease, the method including administering an effective amount
of the compound described in any one of the above [1] to [11]
or a salt thereof, or a solvate thereof to a patient who is in
need of the treatment.
[28] The method described in the above [27], in which the
metabolic disease is type 2 diabetes mellitus, diabetic
complication (diabetic retinopathy, diabetic neuropathy, or
diabetic nephropathy), insulin resistant syndrome, metabolic
syndrome, or hyperinsulinemia.
[29] A method of preventing and/or treating a circulatory
disease and a metabolic disease, the method including
23
administering an effective amount of the compound described in
any one of the above [1] to [11] or a salt thereof, or a solvate
thereof to a patient who is in need of the treatment.
[30] The method described in the above [29], in which the
circulatory disease is hypertension, heart disease, angina
pectoris, cerebral vascular disorder, cerebral circulatory
disorder, ischemic peripheral circulatory disorder, kidney
disease, or arteriosclerosis and the metabolic disease is type
2 diabetes mellitus, diabetic complication (diabetic
retinopathy, diabetic neuropathy, or diabetic nephropathy),
insulin resistant syndrome, metabolic syndrome, or
hyperinsulinemia.
[31] Use of the compound described in any one of the above
[1] to [11] or a salt thereof, or a solvate thereof for producing
a preparation for preventing and/or treating a circulatory
disease.
[32] The use described in the above [31], in which the
circulatory disease is hypertension, heart disease, angina
pectoris, cerebral vascular disorder, cerebral circulatory
disorder, ischemic peripheral circulatory disorder, kidney
disease, or arteriosclerosis.
[0028]
[33] Use of the compound described in any one of the above
[1] to [11] or a salt thereof, or a solvate thereof for producing
a preparation for preventing and/or treating a metabolic
disease.
[34] The use described in the above [33], in which the
24
metabolic disease is type 2 diabetes mellitus, diabetic
complication (diabetic retinopathy, diabetic neuropathy, or
diabetic nephropathy), insulin resistant syndrome, metabolic
syndrome, or hyperinsulinemia.
[35] The compound described in any one the above [1] to
[11] or a salt thereof, or a solvate thereof to be used for a
pharmaceutical composition for preventing and/or treating a
circulatory disease.
[36] The compound described in the above [35] or a salt
thereof, or a solvate thereof, in which the circulatory disease
is hypertension, heart disease, angina pectoris, cerebral
vascular disorder, cerebral circulatory disorder, ischemic
peripheral circulatory disorder, kidney disease, or
arteriosclerosis.
[37] The compound described in the above [35] or [36] or
a salt thereof, or a solvate thereof, in which the effective
component of a pharmaceutical composition is a compound or a
salt thereof, or a solvate thereof having both an angiotensin
II receptor antagonistic activity and a PPAR activation effect.
[38] The compound described in any one of the above [1]
to [11] or a salt thereof, or a solvate thereof to be used for
a pharmaceutical composition for preventing and/or treating a
metabolic disease.
[39] The compound described in the above [38] or a salt
thereof, or a solvate thereof, in which the metabolic disease
is type 2 diabetes mellitus, diabetic complication (diabetic
retinopathy, diabetic neuropathy, or diabetic nephropathy),
25
insulin resistant syndrome, metabolic syndrome, or
hyperinsulinemia.
[40] The compound described in the above [38] or [39] or
a salt thereof, or a solvate thereof, in which the effective
component of a pharmaceutical composition is a compound or a
salt thereof, or a solvate thereof having both an angiotensin
II receptor antagonistic activity and a PPAR activation effect.
[41] The compound described in any one of the above [1]
to [11] or a salt thereof, or a solvate thereof to be used for
a pharmaceutical composition for preventing and/or treating a
circulatory disease or a metabolic disease.
[42] The compound described in the above [41] or a salt
thereof, or a solvate thereof, in which the circulatory disease
is hypertension, heart disease, angina pectoris, cerebral
vascular disorder, cerebral circulatory disorder, ischemic
peripheral circulatory disorder, kidney disease, or
arteriosclerosis and the metabolic disease is type 2 diabetes
mellitus, diabetic complication (diabetic retinopathy,
diabetic neuropathy, or diabetic nephropathy), insulin
resistant syndrome, metabolic syndrome, or hyperinsulinemia.
EFFECTS OF THE INVENTION
[0029]
The phenylpyridine derivative represented by the formula
(I) of the invention or a salt thereof, or a solvate thereof
exhibits a potent antagonistic activity for an angiotensin II
receptor, and can be appropriately used as an effective
26
component of an agent for preventing and/or treating a disease
related with angiotensin II, for example a circulatory disease
such as hypertension, heart disease, angina pectoris, cerebral
vascular disorder, cerebral circulatory disorder, ischemic
peripheral circulatory disorder, kidney disease, and
arteriosclerosis.
[0030]
Further, the phenylpyridine derivative represented by
the formula (I) of the invention or a salt thereof, or a solvate
thereof exhibits a PPAR activation effect and can be
appropriately used as an effective component of an agent for
preventing and/or treating a disease related with PPAR, for
example a metabolic disease such as arteriosclerosis, type 2
diabetes mellitus, diabetic complication (diabetic
retinopathy, diabetic neuropathy, or diabetic nephropathy),
insulin resistance syndrome, syndrome X, metabolic syndrome,
and hyperinsulinemia.
[0031]
Still further, the phenylpyridine derivative represented
by the formula (I) of the invention or a salt thereof, or a
solvate thereof has both an antagonistic activity for an
angiotensin II receptor and a PPAR activation effect and can
be appropriately used as an effective component of an agent for
preventing and/or treating a disease related with both
angiotensin II and PPAR, for example, arteriosclerosis,
diabetic nephropathy, insulin resistance syndrome, syndrome X,
and metabolic syndrome.
27
MODES FOR CARRYING OUT THE INVENTION
[0032]
The “halogen atom” as used herein includes a fluorine atom,
a chlorine atom, a bromine atom, an iodine atom, and the like.
[0033]
The “C1-6 alkyl group” and “C1-6 alkyl” as used herein mean
a linear or a branched hydrocarbon group having 1 to 6 carbon
atoms, preferably a saturated linear or branched hydrocarbon
group having 1 to 6 carbon atoms, and examples thereof include
a methyl group, an ethyl group, an n-propyl group, an isopropyl
group, an n-butyl group, an isobutyl group, a t-butyl group,
an n-pentyl group, a 2-methylbutyl group, a 2,2-dimethylpropyl
group, and an n-hexyl group. Further, the “branched C3-6 alkyl
group” and “branched C3-6 alkyl” as used herein mean a branched
hydrocarbon group having 3 to 6 carbon atoms, preferably a
saturated branched hydrocarbon group having 3 to 6 carbon atoms,
and examples thereof include an isopropyl group, an isobutyl
group, a 2-methylbutyl group, a 2-methylpentyl group, and a
2-ethylbutyl group.
[0034]
The “C3-8 cycloalkyl group” and “C3-8 cycloalkyl” as used
herein mean a saturated or unsaturated and monocyclic,
polycyclic, or fused-cyclic cycloalkyl group having 3 to 8
carbon atoms, and preferably 3 to 6 carbon atoms, and examples
of the cycloalkyl group include a cyclopropyl group, a
cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a
28
cycloheptyl group, and a cyclooctyl group.
[0035]
The “halo C1-6 alkyl group” and “halo C1-6 alkyl” as used
herein mean a linear or a branched alkyl group having 1 to 6
carbon atoms which is substituted with one or more to maximally
substitutable number of halogen atoms, and examples thereof
include a fluoromethyl group, a difluoromethyl group, a
trifluoromethyl group, a 2,2,2-trifluoroethyl group, a
1,1,2,2,2-pentafluoroethyl group, and a 3,3,3-trifluoropropyl
group.
[0036]
The “C1-6 alkoxy group” as used herein means a linear or
a branched alkoxy group having 1 to 6 carbon atoms, and examples
thereof include a methoxy group, an ethoxy group, a propoxy
group, an isopropoxy group, a butoxy group, an isobutoxy group,
a sec-butoxy group, a tert-butoxy group, a pentoxy group, an
isopentoxy group, a neopentoxy group, a hexyloxy group, and an
isohexyloxy group.
[0037]
As used herein, the “substituent group” of the “C1-6 alkoxy
group which may have a substituent group” may be the same or
different from each other, and the alkoxy group may be
substituted with one or more to maximally substitutable number
of substituent groups. Examples of the “substituent group”
include a phenyl group, a hydroxyl group, a C1-6 alkoxy group,
a C1-6 alkylthio group, a C1-6 alkylsulfonyl group, an oxazolyl
group (the oxazolyl group may be substituted with a C1-6 alkyl
29
group, a C6-10 aryl group, or a 5 to 10-memebred heteroaryl group
which may be substituted with a halogen atom), a pyridyl group
(the pyridyl group may be substituted with a C1-6 alkyl group),
a C1-6 alkoxycarbonyl group, a carboxyl group, a carbamoyl group,
a mono C1-6 alkylcarbamoyl group, a di C1-6 alkylcarbamoyl group,
a C1-6 alkanoylamino group, a C1-6 alkylsulfonylamino group, a
halo C1-6 alkylsulfonylamino group, an amide group, and a
sulfonamide group. Preferred examples of the substituent
group include a C1-6 alkylthio group, a C1-6 alkylsulfonyl group,
a carboxyl group, a carbamoyl group, a mono C1-6 alkylcarbamoyl
group, and a di C1-6 alkylcarbamoyl group. Still more preferred
examples of the substituent group include a C1-6 alkylthio group
and a C1-6 alkylsulfonyl group.
[0038]
Preferred modes of the invention include those described
below.
[0039]
In the formula (I), the C1-6 alkyl group as R1 is preferably
a C1-6 alkyl group except butyl group, that is, a C1-3 alkyl group
or a C5-6 alkyl group, and examples thereof include an ethyl group,
an n-propyl group, and an n-pentyl group.
[0040]
In the formula (I), the C1-6 alkyl group as R2 is preferably
a C1-4 alkyl group, and examples thereof include a methyl group,
an ethyl group, and an isopropyl group. An isopropyl group is
particularly preferable. Preferred examples of the C1-6 alkyl
group as R2 include a branched C3-6 alkyl group. An isopropyl
30
group is particularly preferable.
[0041]
In the formula (I), preferred examples of the C3-8
cycloalkyl group as R2 include C3-6 cycloalkyl, for example, a
cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and
a cyclohexyl group. A cyclopropyl group is particularly
preferable.
[0042]
In the formula (I), preferred examples of the C1-6 alkyl
group as R3 and R4 include a C1-4 alkyl group, for example, a
methyl group and an ethyl group.
[0043]
In the formula (I), preferred examples of the halo C1-6
alkyl group as R3 and R4 include a halo C1-4 alkyl group, for
example, a difluoromethyl group, a trifluoromethyl group, and
a 2,2,2-trifluoroethyl group. A trifluoromethyl group is more
preferable.
[0044]
In the formula (I), preferred examples of the “C1-6 alkoxy
group” of the C1-6 alkoxy group which may have a substituent group
as R3 and R4 include a C1-4 alkoxy group, for example, a methoxy
group, an ethoxy group, a propoxy group, an isopropoxy group,
and an n-butoxy group. An ethoxy group is particularly
preferable. Preferred examples of the “substituent group”
include a phenyl group, a hydroxyl group, a C1-6 alkylthio group
(for example, a methylthio group), and a C1-6 alkylsulfonyl group
(for example, a methylsulfonyl group).
31
[0045]
More preferred examples of the compound represented by
the formula (I) include a compound selected from a group
consisting of the following compounds:
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-ethyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-ethylpyrimidin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-isopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-isopropylpyrimidin-4(3H)-o
ne,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H
)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
32
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopentyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclohexyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylthio)ethoxy]pyrimidin-2-yl}pyri
midin-4(3H)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}
pyrimidin-4(3H)-one,
3-{2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihyd
ropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-oxadiazo
l-5(4H)-one,
3-{2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-
oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one,
33
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)
-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
34
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrim
idin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2
-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylsulfonyl)ethoxy]p
yrimidin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyrid
in-2-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-2-methyl-3-(pyridin-2-yl)pyrimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-methoxypyridin-2-yl)-2-methylpyrimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylpy
rimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one,
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(4,6-dimethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)
-one,
3-{2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one,
3-{2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one,
35
3-{2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one,
3-{2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one.
[0046]
More preferred examples of the
5-(pyridinylmethyl)pyrimidin-4(3H)-one derivatives that are
36
represented by the formula (I) include a compound selected from
a group consisting of the following compounds:
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-isopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-isopropylpyrimidin-4(3H)-o
ne,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H
)-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopentyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)
-one,
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclohexyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one,
3-{2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-
37
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)
-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
38
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one.
[0047]
Still more preferred examples of the
5-(pyridinylmethyl)pyrimidin-4(3H)-one derivatives that are
represented by the formula (I) include a compound selected from
a group consisting of the following compounds:
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
39
}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one.
[0048]
If the compound of the invention has geometrical isomers
or optical isomers, all of such isomers are within the scope
of the invention. Isolation of these isomers is carried out
by an ordinary method.
[0049]
Salts of the compound represented by the formula (I) are
not particularly limited, if they are pharmaceutically
acceptable salts. When the compound is processed as an acidic
compound, an alkali metal salt or an alkali earth metal salt
such as sodium salt, potassium salt, magnesium salt, and calcium
salt, and the like; and a salt with an organic base such as
trimethylamine, triethylamine, pyridine, picoline, N-methyl
pyrrolidine, N-methyl piperidine, N-methyl morpholine, and the
like can be mentioned. When the compound is processed as a basic
compound, an acid addition salt and the like including a salt
with a mineral acid, for example, hydrochloric acid salt,
hydrobromic acid salt, hydroiodic acid salt, sulfuric acid salt,
nitric acid salt, phosphoric acid salt, and the like; or organic
acid addition salt, for example, benzoic acid salt,
40
methanesulfonic acid salt, ethanesulfonic acid salt,
benzenesulfonic acid salt, p-toluene sulfonic acid salt, maleic
acid salt, fumaric acid salt, tartaric acid salt, citric acid
salt, and acetic acid salt; or the like can be mentioned.
[0050]
Examples of the solvate of the compound represented by
the formula (I) or a salt thereof include a hydrate, but not
limited thereto.
[0051]
In addition, compounds which are metabolized in a living
body and converted into the compounds represented by the
aforementioned formula (I), so called prodrugs, all fall within
the scope of the compounds of the invention. Examples of groups
which form the prodrugs of the compounds of the invention
include the groups described in “Progress in Medicine”, Vol.
5, pp. 2157-2161, 1985, Life Science Medica, and the groups
described in “Development of Drugs”, Vol. 7, Molecular Designs,
pp. 163-198, published in 1990, Hirokawa Shoten.
[0052]
The compounds represented by the formula (I) or salts
thereof, or solvates thereof can be produced according to
various known methods, and the production method is not
specifically limited. For example, the compounds can be
produced according to the following reaction process. Further,
when each reaction described below is performed, functional
groups other than the reaction sites may be protected beforehand
as required, and deprotected in an appropriate stage.
41
Furthermore, the reaction in each process may be performed by
an ordinarily used method, and isolation and purification can
be performed by a method suitably selected from conventional
methods such as crystallization, recrystallization,
chromatography, or the like, or a combination thereof.
[0053]
(Production method)
1. Method for production of the compound (Ia) in which the ring
B is the formula (IV)
Among the compounds represented by the formula (I) of the
invention, the compound represented by the formula (Ia) can be
produced according to the following method, but it is not
limited thereto. Specifically, as described in the following
Reaction pathway 1, if pyridinyl methyl halide (VI) and
-ketoester (VII) are reacted with each other and the obtained
compound (VIII) are reacted with ammonium acetate followed by
reaction with acid anhydride (IX) or acid chloride (X),
acylamino compound (XI) is obtained. If the acylamino compound
(XI) is reacted with amino compound (XII), pyrimidinone
derivative (XIII) is obtained. If the pyrimidinone derivative
(XIII) is reacted with an azide compound, the compound
represented by the formula (Ia) of the invention can be
obtained.
[Reaction pathway 1]
[0054]
[Chemical Formula 6]
42
[0055]
(in the formula, ring A, R1, R2, R3, R4, and X are as defined
above, R6 represents a protecting group for carboxyl group such
as C1-6 alkyl group, and W represents a leaving group such as
halogen atom).
[0056]
[Process 1] The reaction between the pyridinyl methyl
halide (VI) and the -ketoester (VII) may be carried out in a
solvent in the presence of a base and lithium halide (lithium
chloride, lithium bromide, and the like). The solvent is not
specifically limited, and N,N-dimethyl formamide, N-methyl
pyrrolidone, dimethyl sulfoxide, dioxane, tetrahydrofuran,
acetonitrile, and propionitrile may be used either alone or in
combination thereof. The base is not specifically limited, and
examples thereof which may be used include an organic base such
as pyridine, N,N-dimethylaminopyridine (DMAP), collidine,
43
lutidine, 1,8-diazabicyclo[5.4.0]-7-undecene (DBU),
1,5-diazabicyclo[4.3.0]-5-nonene (DBN),
1,4-diazabicyclo[2.2.2]octane (DABCO), triethylamine,
diisopropylamine, diisopropylethylamine,
diisopropylpentylamine, and trimethylamine, an alkali metal
hydride such as lithium hydride, sodium hydride, and potassium
hydride, an alkali metal hydroxide such as lithium hydroxide,
sodium hydroxide, and potassium hydroxide, an alkali metal
carbonate such as lithium carbonate, sodium carbonate,
potassium carbonate, and cesium carbonate, and an alkali metal
bicarbonate such as sodium hydrogen carbonate. The reaction
condition may vary depending on the reaction materials used.
However, the reaction is generally carried out at -20 to 120C,
and preferably 20C to 100C, for 1 minute to 2 days, and
preferably for 5 minutes to 36 hours to obtain the compound
(VIII).
[0057]
[Process 2-1] The reaction between the compound (VIII)
and ammonium acetate may be carried out in a solvent in the
presence of an acid. The solvent is not specifically limited,
and methanol, ethanol, isopropanol, ethyl acetate, isopropyl
acetate, toluene, benzene, dioxane, tetrahydrofuran,
acetonitrile, propionitrile, N,N-dimethylformamide,
N-methylpyrrolidone, and dimethyl sulfoxide may be used either
alone or in combination thereof. The acid is not specifically
limited, and examples thereof which may be used include a protic
acid such as acetic acid, trifluoro acetic acid, propionic acid,
44
and benzoic acid and Lewis acid such as titanium tetrachloride,
boron trifluoride, and stannic chloride. The reaction
condition may vary depending on the reaction materials used.
However, the reaction is generally carried out at 0 to 180C,
and preferably 50C to 150C, for 1 minute to 24 hours, and
preferably for 5 minutes to 18 hours.
[0058]
[Process 2-2] The reaction between the crude product
obtained after distillation of solvent and the acid anhydride
(IX) may be carried out in the presence of an acid. The acid
is not particularly limited, and examples thereof which may be
used include a protic acid like acetic acid, trifluoroacetic
acid, propionic acid, and benzoic acid. The reaction condition
may vary depending on the reaction materials used. However,
the reaction is generally carried out at 0 to 180C, and
preferably 50C to 120C, for 1 minute to 2 days, and preferably
for 5 minutes to 24 hours to obtain the acylamino compound (XI).
[0059]
The reaction between the crude product obtained after
distillation of solvent and the acid chloride (X) may be carried
out in a solvent in the presence or absence of a base. The
solvent is not specifically limited, and tetrahydrofuran,
toluene, dioxane, N,N-dimethylformamide, N-methylpyrrolidone,
1,2-dichloroethane, dichloromethane, chloroform,
acetonitrile, and propionitrile may be used either alone or in
combination thereof. The base is not specifically limited, and
examples thereof which may be used include an organic base like
45
pyridine, DMAP, collidine, lutidine, DBU, DBN, DABCO,
triethylamine, diisopropylamine, diisopropylethylamine,
diisopropylpentylamine, and trimethylamine, an alkali metal
hydride like lithium hydride, sodium hydride, and potassium
hydride, an alkali metal hydroxide like lithium hydroxide,
sodium hydroxide, and potassium hydroxide, an alkali metal
carbonate like lithium carbonate, sodium carbonate, potassium
carbonate, and cesium carbonate, and sodium hydrogen carbonate.
The reaction condition may vary depending on the reaction
materials used. However, the reaction is generally carried out
at -20 to 100C, and preferably 15 to 80C, for 5 minutes to
48 hours, and preferably for 5 hours to 36 hours to obtain the
acylamino compound (XI).
[0060]
[Process 3] The reaction between the acylamino compound
(XI) obtained according to the method above and the amino
compound (XII) may be carried out in a solvent in the presence
of trialkylaluminum. The solvent is not specifically limited,
and 1,2-dichloroethane, chloroform, dichloromethane, ethyl
acetate, isopropyl acetate, toluene, benzene, tetrahydrofuran,
dioxane, acetonitrile, propionitrile, and hexane may be used
either alone or in combination thereof. Examples of the
trialkylaluminum which may be used include trimethylaluminum,
triethylaluminum, and tripropylaluminum. The reaction
condition may vary depending on the reaction materials used.
However, the reaction is generally carried out at 0 to 150C,
and preferably 50C to 120C, for 1 minute to 24 hours, and
46
preferably for 5 minutes to 20 hours to obtain the pyrimidinone
derivative (XIII).
[0061]
[Process 4] The reaction between the pyrimidinone
derivative (XIII) and an azide compound may be carried out in
a solvent. Examples of the azide compound which may be used
include trimethyltin azide, tributyltin azide, triphenyltin
azide, sodium azide, and hydrogen azide. Further,
trimethylsilyl azide may be used in the presence of dibutyltin
oxide. The solvent is not specifically limited, and methanol,
ethanol, isopropanol, ethyl acetate, isopropyl acetate,
toluene, benzene, dioxane, tetrahydrofuran, acetonitrile,
propionitrile, N,N-dimethylformamide, N-methylpyrrolidone,
and dimethyl sulfoxide may be used either alone or in
combination thereof. The reaction condition may vary
depending on the reaction materials used. However, the
reaction is generally carried out at 0 to 180C, and preferably
50 to 120C, for 1 minute to 2 weeks, and preferably for 1 hour
to 3 days to obtain the target compound.
[0062]
2. Method for production of the compound (Ib) in which the ring
B is the formula (V)
Among the compounds represented by the formula (I) of the
invention, the compound represented by the formula (Ib) can be
produced according to the following method, but it is not
limited thereto. Specifically, as described in the following
Reaction pathway 2, if the pyrimidinone derivative (XIII) and
47
hydroxylamine are reacted with each other, amide oxime product
(XIV) is obtained. If the amide oxime product (XIV) is reacted
with a carbonyl reagent, the compound represented by the formula
(Ib) of the invention can be produced.
[Reaction pathway 2]
[0063]
[Chemical Formula 7]
[0064]
(in the formula, ring A, R1, R2, R3, R4, and X are as defined
above).
[0065]
[Process 5] The reaction between the pyrimidinone
derivative (XIII) and hydroxylamine may be carried out in a
solvent. The solvent is not specifically limited, and
N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl
pyrrolidone, dimethyl sulfoxide, methanol, ethanol,
isopropanol, 1,4-dioxane, and tetrahydrofuran may be used
either alone or in combination thereof. When an acid salt such
as hydroxylamine hydrochloride, hydroxylamine sulfuric acid,
hydroxylamine oxalic acid, and the like is used as hydroxylamine,
a suitable base, for example, potassium carbonate, sodium
48
hydrogen carbonate, sodium hydroxide, triethylamine, sodium
methoxide, sodium hydride, and the like may be used in an
equivalent amount or a slightly excess amount for the reaction.
The reaction condition may vary depending on the reaction
materials used. However, the reaction is generally carried out
at 0 to 180C, and preferably 50 to 120C, for 1 minute to 3
days, and preferably for 1 hour to 36 hours. As a result, the
amide oxime product (XIV) is obtained.
[0066]
[Process 6] Conversion of the amide oxime product (XIV)
to the compound (Ib) can be carried out in a solvent in the
presence of a base by using a carbonyl reagent. The solvent
is not specifically limited, and 1,2-dichloroethane,
chloroform, dichloromethane, ethyl acetate, isopropyl acetate,
toluene, benzene, tetrahydrofuran, dioxane, acetonitrile,
propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide,
N-methylpyrrolidone, diethyl ether, or the like may be used
either alone or in combination thereof. The base is not
specifically limited, and examples thereof which may be used
include pyridine, DMAP, collidine, lutidine, DBU, DBN, DABCO,
triethylamine, diisopropylethylamine, diisopropylpentylamine,
trimethylamine, lithium carbonate, sodium carbonate,
potassium carbonate, cesium carbonate, sodium hydrogen
carbonate, potassium hydrogen carbonate, or the like. The
carbonyl reagent is not specifically limited, and
1,1’-carbonyldiimidazole, triphosgene, methyl
chlorocarbonate, ethyl chlorocarbonate, or the like may be used.
49
The reaction condition may vary depending on the reaction
materials used. However, the reaction is generally carried out
at 0 to 120C, preferably 15 to 80C for 5 minutes to 3 days,
and preferably for 1 hour to 12 hours to obtain the compound
(Ib).
[0067]
If necessary, the intermediates and target compounds that
are obtained from each of the reaction above can be isolated
and purified by a purification method that is generally used
in a field of organic synthesis chemistry, for example,
filtration, extraction, washing, drying, concentration,
recrystallization, various chromatographic methods, and the
like. Furthermore, the intermediates may be used for the next
reaction without any specific purification.
[0068]
Various isomers may be isolated by applying a general
method based on a difference in physicochemical properties
among the isomers. For example, a racemic mixture may be
resolved into an optically pure isomer by common racemic
resolution such as optical resolution by which a diastereomer
salt is formed with a common optically active acid such as
tartaric acid or a method of using optically active
chromatography. Further, a mixture of diastereomers can be
resolved by fractional crystallization or various
chromatographic methods, for example. Furthermore, an
optically active compound can be also produced by using an
appropriate starting compound that is optically active.
50
[0069]
The compound (I) obtained may be converted into a salt
according to a common method. Furthermore, the compound (I)
or a salt thereof may be converted into a solvate with a hydrate
or a solvate with ethanol according to a common method.
[0070]
Examples of dosage form or administration type of the
pharmaceutical composition containing the compounds of the
invention or salts thereof, or solvates thereof as an effective
component include, for example, those for oral administration
such as tablet, capsule, granule, powder, syrup, or the like
and those for parenteral administration such as intravenous
injection, intramuscular injection, suppository, inhalant,
transdermal preparation, eye drop, nasal drop, or the like. In
order to prepare a pharmaceutical preparation in the various
dosage forms, the effective component may be used alone, or may
be used in appropriate combination with other pharmaceutically
acceptable carriers such as excipients, binders, extending
agents, disintegrating agents, surfactants, lubricants,
dispersing agents, buffering agents, preservatives,
corrigents, perfumes, coating agents, diluents, and the like
to give a pharmaceutical composition.
[0071]
Although the administration amount of the pharmaceutical
agent of the invention may vary depending on the weight, age,
sex, symptoms, and the like of a patient, in terms of the compound
represented by the formula (I), generally 0.1 to 1000 mg,
51
especially 1 to 300 mg, may be administered orally or
parenterally at one time or several times as divided portions
per day for an adult.
EXAMPLES
[0072]
Herein below, the invention will be described in greater
detail with reference to examples. However, the invention is
not limited to these examples. The abbreviations used in the
examples have the following meanings.
s: singlet
d: doublet
t: triplet
q: quartet
m: multiplet
br: broad
J: coupling constant
Hz: Hertz
CDCl3: deuterated chloroform
DMSO-d6: deuterated dimethylsulfoxide
1H-NMR: proton nuclear magnetic resonance
IR: infrared absorption spectrum
[0073]
Example 1 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
[0074]
52
[Chemical Formula 8]
[0075]
Process 1: Under argon atmosphere, tetrahydrofuran (900
mL) solution of 2-[5-(bromomethyl)pyridin-2-yl]benzonitrile
(31.9 g, 117 mmol), methyl 3-oxoheptanoate (27.8 g, 176 mmol),
diisopropylethylamine (31.0 g, 240 mmol), and lithium chloride
(8.2 g, 193 mmol) was refluxed under heating for 23 hours. The
reaction mixture was added water and extracted with ethyl
acetate. The organic layer was combined, washed with water and
brine, dried over anhydrous sodium sulfate, and concentrated
in vacuo. The obtained residues were subjected to silica gel
column chromatography (hexane/ethyl acetate = 2 : 1) to give
methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxoheptanoate
(20.9 g, 51%) as brown oil.
[0076]
1H-NMR(CDCl3, 400 MHz):
0.87(3H, t, J = 7 Hz), 1.18 - 1.32(2H, m), 1.47 - 1.59(2H, m),
2.34 - 2.39(1H, m), 2.55 - 2.67(1H, m), 3.20 - 3.29(2H, m),
53
3.73(3H, s), 3.84(1H, t, J = 7 Hz), 7.50(1H, td, J = 8, 1 Hz),
7.63 - 7.74(3H, m), 7.76 - 7.87(2H, m), 8.61(1H, s).
[0077]
Process 2: Toluene (50 mL)-acetic acid (7 mL) solution
of methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxoheptanoate
(3.50 g, 10.0 mmol) and ammonium acetate (23.2 g, 300 mmol) was
refluxed under heating for 1 hour. To the residues obtained
after distillation of solvent, acetic anhydride (51.2 g) and
acetic acid (5.7 g) were added at room temperature followed by
stirring for 30 minutes at 0C and then stirring for 1.5 hours
at 70C. The reaction mixture was added sodium bicarbonate
water, and then extracted with chloroform. The organic layer
was combined, washed with brine, dried over anhydrous sodium
sulfate, and concentrated in vacuo. The obtained residues were
subjected to silica gel column chromatography (hexane/acetone
= 5 : 1) to give methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate (0.975 g, 25%) as pale yellow oil.
[0078]
1H-NMR(CDCl3, 400 MHz):
0.91(3H, t, J = 7 Hz), 1.33 - 1.45(2H, m), 1.46 - 1.57(2H, m),
2.18(3H, s), 2.94(2H, t, J = 6 Hz), 3.71(3H, s), 3.75(2H, s),
7.50(1H, t, J = 8 Hz), 7.58(1H, d, J = 8 Hz), 7.63 - 7.72(2H,
m), 7.75 - 7.83(2H, m), 8.60(1H, s), 11.9(1H, s).
[0079]
Process 3: Under argon atmosphere, trimethylaluminum (2
54
mol/L hexane solution, 1.45 mL, 2.90 mmol) was added to
1,2-dichloroethane (30 mL) solution of
2-amino-5-methoxypyrimidine (220 mg, 1.74 mmol) at room
temperature, and stirred at the same temperature for 80 minutes.
1,2-Dichloroethane solution (20 mL) of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate (227 mg, 0.58 mmol) was added dropwise thereto at
room temperature and refluxed under heating for 17 hours. The
reaction mixture was added an aqueous solution of ammonium
chloride and chloroform and filtered through a pad of celite.
The organic layer was separated from the filtrate and the
aqueous layer was extracted with chloroform. The organic layer
was combined, washed with water and brine, dried over anhydrous
sodium sulfate, and concentrated in vacuo. The obtained
residues were subjected to silica gel column chromatography
(hexane/ethyl acetate = 2 : 1) to give
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(207 mg, 77%) as yellow oil.
[0080]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.36 - 1.48(2H, m), 1.58 - 1.70(2H, m),
2.16(3H, s), 2.63 - 2.72(2H, m), 3.97(2H, s), 4.01(2H, s),
7.47(1H, m), 7.60 - 7.71(2H, m), 7.72 - 7.83(3H, m), 8.54(2H,
s), 8.70(1H, d, J = 1 Hz).
[0081]
Process 4: Trimethylsilyl azide (8.68 g, 75.3 mmol) and
55
dibutyltin oxide (55 mg, 0.221 mmol) were added to toluene (20
mL) solution of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(200 mg, 0.43 mmol) and stirred for 24 hours at 95C under argon
atmosphere. The residues obtained by removing the reaction
solvent by distillation was separated and purified by silica
gel column chromatography (chloroform : methanol = 100 : 1) to
give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
(174 mg, 80%) as yellow oil.
[0082]
1H-NMR(CDCl3, 400 MHz):
0.93(3H, t, J = 7 Hz), 1.33 - 1.48(2H, m), 1.55 - 1.73(2H, m),
2.16(3H, s), 2.58 - 2.72(2H, m), 3.95(2H, s), 4.00(3H, s), 7.20
- 7.35(1H, m), 7.38 - 7.58(3H, m), 7.62 - 7.82(1H, m), 8.00 -
8.22(1H, m), 8.54(2H, s), 8.50 - 8.63(1H, m).
[0083]
Example 2 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
[0084]
[Chemical Formula 9]
56
[0085]
Process 1: By using 2-amino-5-ethoxypyrimidine instead
of 2-amino-5-methoxypyridine in the Process 3 of the Example
1, the reaction and the treatment were performed in the same
manner as the Process 3 of the Example 1 to give
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(yield: 46%).
[0086]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.38 - 1.46(2H, m), 1.51(3H, t, J = 7
Hz), 1.60 - 1.68(2H, m), 2.16(3H, s), 2.65 - 2.69(2H, m), 3.97(2H,
s), 4.22(2H, q, J = 7 Hz), 7.47(1H, m), 7.64 - 7.81(5H, m),
8.51(2H, s), 8.70(1H, d, J = 1 Hz).
[0087]
Process 2: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
57
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
(yield: 46%) as pale yellow amorphous.
[0088]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.38 - 1.44(2H, m), 1.51(3H, t, J = 7
Hz), 1.61 - 1.68(2H, m), 2.17(3H, s), 2.66 - 2.70(2H, m), 3.97(2H,
s), 4.22(2H, q, J = 7 Hz), 7.37(1H, m), 7.48 - 7.58(3H, m),
7.78(1H, m), 8.21(1H, m), 8.51(2H, s), 8.62(1H, m).
[0089]
Example 3 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-ethyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-one
[0090]
[Chemical Formula 10]
[0091]
58
Process 1: Toluene (36 mL)-acetic acid (4 mL) solution
of methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxoheptanoate
(1.03 g, 2.94 mmol) obtained from the Process 1 of the Example
1 and ammonium acetate (6.80 g, 88.2 mmol) was refluxed under
heating for 1 hour. The residues obtained by removing solvent
by distillation were added water and 2 mol/L aqueous solution
of sodium hydroxide and extracted with chloroform. Propionyl
chloride (544 mg, 5.88 mmol) and triethylamine (595 mg, 5.88
mmol) were added to the 1,2-dichloroethane (10 mL) solution of
the residues obtained by removing solvent by distillation and
stirred for 16 hours at 50C. The reaction mixture was added
water and extracted with chloroform. The organic layer was
combined, washed with brine, dried over anhydrous sodium
sulfate, and concentrated in vacuo. The obtained residues were
subjected to silica gel column chromatography (hexane/acetone
= 5 : 1) to give methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-propionamid
e-2-heptenoate (464 mg, 39%) as brown oil.
[0092]
1H-NMR(CDCl3, 400 MHz):
0.91(3H, t, J = 7 Hz), 1.23(3H, t, J = 8 Hz), 1.34 - 1.51(4H,
m), 2.43 (2H, q, J = 8 Hz), 2.89 - 2.99(2H, m), 3.70(3H, s),
3.75(2H, s), 7.49 (1H, td, J = 8, 1 Hz), 7.58(1H, dd, J = 8,
2 Hz), 7.64 - 7.73(2H, m), 7.77 - 7.86(2H, m), 8.60(1H, s),
11.88(1H, s).
[0093]
59
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-propionamid
e-2-heptenoate instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1, the reaction and
the treatment were performed in the same manner as the Process
3 of the Example 1 to give
2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(yield: 70%) as a pale yellow solid.
[0094]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.18(3H, t, J = 7 Hz), 1.35 - 1.46(2H,
m), 1.62 - 1.74(2H, m), 2.32(2H, q, J = 7 Hz), 2.69(2H, t, J
= 8 Hz), 3.96(2H, s), 4.00(3H, s), 7.47(1H, td, J = 8, 1 Hz),
7.61 - 7.70(2H, m), 7.73 - 7.82(3H, m), 8.53(2H, s), 8.69(1H,
s).
[0095]
Process 3: By using
2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
60
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-ethyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-one
(yield: 60%) as colorless viscous oil.
[0096]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.18(3H, t, J = 7 Hz), 1.34 - 1.47(2H,
m), 1.60 - 1.75 (2H, m), 2.32(2H, q, J = 7 Hz), 2.70(2H, t, J
= 8 Hz), 3.96(2H, s), 4.01 (3H, s), 7.29 - 7.38(1H, m), 7.43
- 7.59(3H, m), 7.76(1H, d, J = 8 Hz), 8.18 (1H, s), 8.54(2H,
s), 8.61(1H, br s).
[0097]
Example 4 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-ethylpyrimidin-4(3H)-one
[0098]
[Chemical Formula 11]
[0099]
Process 1: By using 2-amino-5-ethoxypyrimidine instead
of 2-amino-5-methoxypyrimidine in the Process 2 of the Example
61
3, the reaction and the treatment were performed in the same
manner as the Process 2 of the Example 3 to give
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(yield: 80%) as a pale yellow solid.
[0100]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.18(3H, t, J = 7 Hz), 1.37 - 1.47(2H,
m), 1.51(3H, t, J = 7 Hz), 1.62 - 1.72(2H, m), 2.32(2H, q, J
= 7 Hz), 2.66 - 2.72(2H, m), 3.97(2H, s), 4.22(2H, q, J = 7 Hz),
7.47(1H, t, J = 8 Hz), 7.64 - 7.69(2H, m), 7.74 - 7.83(3H, m),
8.51(2H, s), 8.70(1H, d, J = 2 Hz).
[0101]
Process 2: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-ethylpyrimidin-4(3H)-one
(yield: 75%) as colorless viscous oil.
[0102]
1H-NMR(CDCl3, 400 MHz):
62
0.94(3H, t, J = 7 Hz), 1.18(3H, t, J = 7 Hz), 1.36 - 1.47(2H,
m), 1.51(3H, t, J = 7 Hz), 1.61 - 1.74(2H, m), 2.33(2H, q, J
= 7 Hz), 2.70(2H, t, J = 8 Hz), 3.97(2H, s), 4.22(2H, q, J =
7 Hz), 7.38(1H, d, J = 8 Hz), 7.47 - 7.60(3H, m), 7.78(1H, dd,
J = 8, 2 Hz), 8.20 - 8.28(1H, m), 8.51(2H, s), 8.64(1H, s).
[0103]
Example 5 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-isopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-
one
[0104]
[Chemical Formula 12]
[0105]
Process 1: By using isobutyryl chloride instead of
propionyl chloride in the Process 1 of the Example 3, the
reaction and the treatment were performed in the same manner
as the Process 1 of the Example 3 to give methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-heptenoate (yield: 49%) as brown oil.
63
[0106]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.25(6H, d, J = 7 Hz), 1.33 - 1.55(4H,
m), 2.49 - 2.63(1H, m), 2.90 - 2.99(2H, m), 3.71(3H, s), 3.75(2H,
s), 7.49(1H, td, J = 8, 1 Hz), 7.59(1H, dd, J = 8, 2 Hz), 7.64
- 7.73(2H, m), 7.79(1H, dd, J = 8, 1 Hz), 7.83(1H, dd, J = 8,
1 Hz), 8.61(1H, d, J = 1 Hz), 11.90(1H, s).
[0107]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-heptenoate instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1, the reaction and
the treatment were performed in the same manner as the Process
3 of the Example 1 to give
2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e (yield: 55%) as yellow oil.
[0108]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.20(6H, d, J = 7 Hz), 1.33 - 1.49(2H,
m), 1.62 - 1.75 (2H, m), 2.21 - 2.35(1H, m), 2.69(2H, t, J =
8 Hz), 3.95(2H, s), 4.00(3H, s), 7.46(1H, td, J = 8, 1 Hz), 7.61
- 7.70(2H, m), 7.74 - 7.83(3H, m), 8.53(2H, s), 8.69(1H, d, J
= 1 Hz).
[0109]
Process 3: By using
64
2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-isopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)-
one (yield: 69%) as colorless viscous oil.
[0110]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.20(6H, d, J = 7 Hz), 1.33 - 1.47(2H,
m), 1.60 - 1.75 (2H, m), 2.22 - 2.35(1H, m), 2.70(2H, t, J =
8 Hz), 3.95(2H, s), 4.01(3H, s), 7.33(1H, d, J = 8 Hz), 7.45
- 7.57(3H, m), 7.77(1H, d, J = 7 Hz), 8.18(1H, br s), 8.53(2H,
s), 8.61(1H, s).
[0111]
Example 6 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-isopropylpyrimidin-4(3H)-o
ne
[0112]
[Chemical Formula 13]
65
[0113]
Process 1: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-heptenoate obtained from the Process 1 of the Example 5
instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1 and also using
2-amino-5-ethoxypyrimidine instead of
2-amino-5-methoxypyrimidine, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
1 to give
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(yield: 79%) as a pale yellow solid.
[0114]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.19(6H, d, J = 7 Hz), 1.35 - 1.45(2H,
m), 1.51 (3H, t, J = 7 Hz), 1.63 - 1.74(2H, m), 2.22 - 2.35(1H,
m), 2.69(2H, t, J = 8 Hz), 3.95(2H, s), 4.22(2H, q, J = 7 Hz),
66
7.46(1H, td, J = 8, 1 Hz), 7.62 - 7.70(2H, m), 7.75 - 7.83(3H,
m), 8.50(2H, s), 8.67 - 8.71(1H, m).
[0115]
Process 2: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-isopropylpyrimidin-4(3H)-o
ne (yield: 99%) as pale brown viscous oil.
[0116]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.20(6H, d, J = 7 Hz), 1.35 - 1.46(2H,
m), 1.51(3H, t, J = 7 Hz), 1.63 - 1.75(2H, m), 2.22 - 2.35(1H,
m), 2.71(2H, t, J = 7 Hz), 3.96(2H, s), 4.22(2H, q, J = 7 Hz),
7.37 - 7.45(1H, m), 7.48 - 7.63(3H, m), 7.81(1H, dd, J = 8, 2
Hz), 8.25 - 8.33(1H, m), 8.51(2H, s), 8.67 (1H, s).
[0117]
Example 7 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H
)-one
67
[0118]
[Chemical Formula 14]
[0119]
Process 1: By using cyclopropanecarbonyl chloride
instead of propionyl chloride in the Process 1 of the Example
3, the reaction and the treatment were performed in the same
manner as the Process 1 of the Example 3 to give methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclopropa
necarboxamide)-2-heptenoate (yield: 69%) as yellow oil.
[0120]
1H-NMR(CDCl3, 400 MHz):
0.78 - 0.98(5H, m), 1.02 - 1.12(2H, m), 1.31 - 1.65(5H, m), 2.88
- 3.02(2H, m), 3.72(3H, s), 3.76(2H, s), 7.50(1H, t, J = 8 Hz),
7.60(1H, d, J = 8 Hz), 7.63 - 7.74(2H, m), 7.76 - 7.87(2H, m),
8.61(1H, s), 12.2(1H, s).
[0121]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclopropa
necarboxamide)-2-heptenoate instead of methyl
68
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1, the reaction and
the treatment were performed in the same manner as the Process
3 of the Example 1 to give
2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitr
ile (yield: 63%) as yellow oil.
[0122]
1H-NMR(CDCl3, 400 MHz):
0.82 - 0.87(2H, m), 0.92(3H, t, J = 7 Hz), 1.07 - 1.15(1H, m),
1.21 - 1.27 (2H, m), 1.32 - 1.41(2H, m), 1.53 - 1.64(2H, m),
2.61(2H, t, J = 8 Hz), 3.94(2H, s), 4.01(3H, s), 7.44 - 7.49(1H,
m), 7.66(2H, t, J = 8 Hz), 7.74 - 7.82(3H, m), 8.56(2H, s),
8.68(1H, d, J = 2 Hz).
[0123]
Process 3: By using
2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitr
ile instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopropyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H
)-one (yield: 100%) as pale yellow viscous oil.
69
[0124]
1H-NMR(CDCl3, 400 MHz):
0.82 - 0.89(2H, m), 0.92(3H, t, J = 7 Hz), 1.06 - 1.15(1H, m),
1.21 - 1.27 (2H, m), 1.31 - 1.43(2H, m), 1.56 - 1.67(2H, m),
2.63(2H, t, J = 8 Hz), 3.94(2H, s), 4.01(3H, s), 7.40(1H, d,
J = 8 Hz), 7.47 - 7.62(3H, m), 7.75 - 7.82(1H, m), 8.23 - 8.32(1H,
m), 8.56(2H, s), 8.65(1H, s).
[0125]
Example 8 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)
-one
[0126]
[Chemical Formula 15]
[0127]
Process 1: By using cyclobutanecarbonyl chloride instead
of propionyl chloride in the Process 1 of the Example 3, the
reaction and the treatment were performed in the same manner
as the Process 1 of the Example 3 to give methyl
70
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclobutan
ecarboxamide)-2-heptenoate (yield: 72%) as brown oil.
[0128]
1H-NMR(CDCl3, 400 MHz):
0.91(3H, t, J = 7 Hz), 1.33 - 1.54(4H, m), 2.19 - 2.44(6H, m),
2.95(2H, t, J = 8 Hz), 3.12 - 3.25(1H, m), 3.70(3H, s), 3.75(2H,
s), 7.49(1H, td, J = 8, 1 Hz), 7.58(1H, dd, J = 8, 2 Hz), 7.64
- 7.73(2H, m), 7.76 - 7.86(2H, m), 8.60(1H, s), 11.78(1H, s).
[0129]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclobutan
ecarboxamide)-2-heptenoate instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1, the reaction and
the treatment were performed in the same manner as the Process
3 of the Example 1 to give
2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le (yield: 65%) as a pale yellow solid.
[0130]
1H-NMR(CDCl3, 400 MHz):
0.96(3H, t, J = 7 Hz), 1.34 - 1.51(2H, m), 1.65 - 1.83(6H, m),
2.36 - 2.51(2H, m), 2.71(2H, t, J = 8 Hz), 3.07 - 3.17(1H, m),
3.96(2H, s), 4.00 (3H, s), 7.46(1H, td, J = 8, 1 Hz), 7.61 -
7.70(2H, m), 7.73 - 7.82(3H, m), 8.52(2H, s), 8.69(1H, d, J =
1 Hz).
[0131]
71
Process 3: By using
2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-methoxypyrimidin-2-yl)pyrimidin-4(3H)
-one (yield: 74%) as colorless viscous oil.
[0132]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.34 - 1.50(2H, m), 1.65 - 1.83(6H, m),
2.37 - 2.51 (2H, m), 2.72(2H, t, J = 8 Hz), 3.04 - 3.20(1H, m),
3.96(2H, s), 4.01(3H, s), 7.31(1H, d, J = 8 Hz), 7.45 - 7.56(3H,
m), 7.76(1H, d, J = 8 Hz), 8.16(1H, br s), 8.52(2H, s), 8.59(1H,
s).
[0133]
Example 9 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one
[0134]
[Chemical Formula 16]
72
[0135]
Process 1: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclobutan
ecarboxamide)-2-heptenoate obtained from the Process 1 of the
Example 8 instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1 and also using
2-amino-5-ethoxypyrimidine instead of
2-amino-5-methoxypyrimidine, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
1 to give
2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e (yield: 89%) as a pale yellow solid.
[0136]
1H-NMR(CDCl3, 400 MHz):
0.96(3H, t, J = 7 Hz), 1.39 - 1.47(2H, m), 1.51(3H, t, J = 7
Hz), 1.61 - 1.84 (6H, m), 2.36 - 2.51(2H, m), 2.67 - 2.75(2H,
m), 3.03 - 3.16(1H, m), 3.96(2H, s), 4.22(2H, q, J = 7 Hz),
73
7.48(1H, dd, J = 8, 1 Hz), 7.62 - 7.70 (2H, m), 7.72 - 7.83(3H,
m), 8.49(2H, s), 8.69(1H, d, J = 2 Hz).
[0137]
Process 2: By using
2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclobutyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one (yield: 99%) as pale brown viscous oil.
[0138]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.36 - 1.47(2H, m), 1.51(3H, t, J = 7
Hz), 1.63 - 1.85 (6H, m), 2.37 - 2.50(2H, m), 2.73(2H, t, J =
8 Hz), 3.07 - 3.18(1H, m), 3.97(2H, s), 4.22(2H, q, J = 7 Hz),
7.40(1H, d, J = 8 Hz), 7.48 - 7.62(3H, m), 7.76 - 7.82(1H, m),
8.24 - 8.31(1H, m), 8.49(2H, s), 8.66(1H, s).
[0139]
Example 10 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclopentyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)
-one
74
[0140]
[Chemical Formula 17]
[0141]
Process 1: By using cyclopentanecarbonyl chloride
instead of propionylchloride in the Process 1 of the Example
3, the reaction and the treatment were performed in the same
manner as the Process 1 of the Example 3 to give methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclopenta
necarboxamide)-2-heptenoate (yield: 44%) as brown oil.
[0142]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.33 - 2.03(12H, m), 2.70 - 2.82(1H, m),
2.89 - 2.99 (2H, m), 3.71(3H, s), 3.75(2H, s), 7.49(1H, td, J
= 8, 1 Hz), 7.59(1H, dd, J = 8, 2 Hz), 7.64 - 7.73(2H, m), 7.76
- 7.86(2H, m), 8.60(1H, s), 11.89(1H, s).
[0143]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclopenta
necarboxamide)-2-heptenoate instead of methyl
75
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1 and also using
2-amino-5-ethoxypyrimidine instead of
2-amino-5-methoxypyrimidine, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
1 to give
2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le (yield: 57%) as a pale yellow solid.
[0144]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.34 - 1.54(7H, m), 1.60 - 1.80(6H, m),
1.90 - 2.03 (2H, m), 2.42 - 2.48(1H, m), 2.64 - 2.70(2H, m),
3.95(2H, s), 4.22(2H, q, J = 7 Hz), 7.47(1H, td, J = 8, 1 Hz),
7.63 - 7.69(2H, m), 7.77(2H, dd, J = 8, 1 Hz), 7.80(1H, dd, J
= 8, 1 Hz), 8.51(2H, s), 8.69(1H, d, J = 2 Hz).
[0145]
Process 3: By using
2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
76
tyl-2-cyclopentyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)
-one (yield: 40%) as pale yellow amorphous.
[0146]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.52(3H, t, J = 7 Hz), 1.57 - 1.78(8H,
m), 1.81 - 1.93(5H, m), 2.70(2H, t, J = 8 Hz), 3.94(2H, s),
4.23(2H, q, J = 7 Hz), 7.38(1H, d, J = 9 Hz), 7.47 - 7.62(3H,
m), 7.78(1H, d, J = 8 Hz), 8.22 - 8.29(1H, m), 8.52(2H, s),
8.65(1H, s).
[0147]
Example 11 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclohexyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one
[0148]
[Chemical Formula 18]
[0149]
Process 1: By using cyclohexanecarbonyl chloride instead
of propionyl chloride in the Process 1 of the Example 3, the
77
reaction and the treatment were performed in the same manner
as the Process 1 of the Example 3 to give methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclohexan
ecarboxyamide)-2-heptenoate (yield: 52%) as brown oil.
[0150]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.16 - 2.03(14H, m), 2.45 - 2.59(1H, m),
2.89 - 2.98(2H, m), 3.71(3H, s), 3.75(2H, s), 7.49(2H, td, J
= 8, 1 Hz), 7.58(1H, dd, J = 8, 2 Hz), 7.63 - 7.74(2H, m), 7.76
- 7.86(2H, m), 8.61(1H, s), 11.84(1H, br s).
[0151]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclohexan
ecarboxyamide)-2-heptenoate instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1 and also using
2-amino 5-ethoxypyrimidine instead of 2-amino
5-methoxypyrimidine, the reaction and the treatment were
performed in the same manner as the Process 3 of the Example
1 to give
2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e (yield: 80%) as a pale yellow solid.
[0152]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.16 - 1.91(17H, m), 2.65 - 2.71(2H, m),
3.95(2H, s), 4.23(2H, q, J = 7 Hz), 7.47(1H, td, J = 8, 1 Hz),
78
7.63 - 7.68(2H, m), 7.75 - 7.82(3H, m), 8.51(2H, s), 8.69(1H,
d, J = 1 Hz).
[0153]
Process 3: By using
2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-cyclohexyl-3-(5-ethoxypyrimidin-2-yl)pyrimidin-4(3H)-
one (yield: 58%) as colorless viscous oil.
[0154]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.51(3H, t, J = 7 Hz), 1.61 - 1.82(8H,
m), 1.90 - 2.05(5H, m), 2.46(2H, t, J = 8 Hz), 2.69(2H, t, J
= 7 Hz), 3.95(2H, s), 4.22(2H, q, J = 7 Hz), 7.39(1H, d, J =
8 Hz), 7.48 - 7.62(3H, m), 7.79(1H, dd, J = 8, 2 Hz), 8.22 -
8.31(1H, m), 8.51(2H, s), 8.65(1H, s).
[0155]
Example 12 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylthio)ethoxy]pyrimidin-2-yl}pyri
midin-4(3H)-one
79
[0156]
[Chemical Formula 19]
[0157]
Process 1: By using
2-amino-5-[2-(methylthio)ethoxy]pyrimidine instead of
2-amino-5-methoxypyridine in the Process 3 of the Example 1,
the reaction and the treatment were performed in the same manner
as the Process 3 of the Example 1 to give
2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrimidi
n-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2-yl
}benzonitrile (yield: 64%) as yellow oil.
[0158]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.33 - 1.48(2H, m), 1.57 - 1.73(2H, m),
2.17(3H, s), 2.24(3H, s), 2.67(2H, t, J = 8 Hz), 2.96(2H, t,
J = 7 Hz), 3.97(2H, s), 4.33(2H, t, J = 7 Hz), 7.47(1H, t, J
= 8 Hz), 7.62 - 7.70(2H, m), 7.73 - 7.83(3H, m), 8.55(2H, s),
8.70(1H, s).
[0159]
80
Process 2: By using
2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrimidi
n-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2-yl
}benzonitrile instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylthio)ethoxy]pyrimidin-2-yl}pyri
midin-4(3H)-one (yield: 80%) as yellow oil.
[0160]
1H-NMR(CDCl3, 400 MHz):
0.82 - 1.00(3H, m), 1.33 - 1.47(2H, m), 1.55 - 1.73(2H, m),
2.15(3H, s), 2.23(3H, s), 2.55 - 2.76(2H, m), 2.95(2H, t, J =
7 Hz), 3.82 - 4.03(2H, m), 4.33(2H, t, J = 7 Hz), 7.07 - 7.33(1H,
m), 7.35 - 7.57(3H, m), 7.59 - 7.80(1H, m), 7.85 - 8.15(1H, m),
8.47 - 8.62(1H, m), 8.55(2H, s).
[0161]
Example 13 Preparation of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}
pyrimidin-4(3H)-one
[0162]
[Chemical Formula 20]
81
[0163]
Methanol (0.4 mL) solution of hydrogen peroxide (30%
solution, 24 mg, 0.211 mmol) and methanol (0.4 mL) solution of
tantalum chloride (1.5 mg, 0.0042 mmol) were added to methanol
(1.0) solution of
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylthio)ethoxy]pyrimidin-2-yl}pyri
midin-4(3H)-one (24 mg, 0.042 mmol) which has been obtained in
the Example 12. After stirring for 12 hours at room temperature,
the solvent was removed by distillation. The obtained residues
were subjected to silica gel column chromatography
(chloroform : methanol : triethylamine = 4 : 1 : 0.4) to give
5-{{6-[2-(1H-tetrazol-5-yl)phenyl]pyridin-3-yl}methyl}-6-bu
tyl-2-methyl-3-{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}
pyrimidin-4(3H)-one (24 mg, 93%) as pale yellow amorphous.
[0164]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.34 - 1.47(2H, m), 1.54 - 1.71(2H, m),
2.16(3H, s), 2.66(2H, t, J = 8 Hz), 3.09(3H, s), 3.55(2H, t,
J = 5 Hz), 3.93(2H, s), 4.64(2H, t, J = 5 Hz), 7.10 - 7.24(1H,
m), 7.31 - 7.55(3H, m), 7.65 - 7.77(1H, m), 7.92 - 8.04(1H, m),
82
8.45 - 8.53(1H, m), 8.59(2H, s).
[0165]
Example 14 Preparation of
3-{2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihyd
ropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-oxadiazo
l-5(4H)-one
[0166]
[Chemical Formula 21]
[0167]
Process 1: By using 2-amino-pyridine instead of
2-amino-5-methoxypyrimidine in the Process 3 of the Example 1,
the reaction and the treatment were performed in the same manner
as the Process 3 of the Example 1 to give
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile (yield: 61%).
[0168]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.43(2H, sextet, J = 8 Hz), 1.61 - 1.69(2H,
m), 2.17(3H, s), 2.66 - 2.70(2H, m), 3.97(2H, s), 7.36 - 7.50(3H,
83
m), 7.65 - 7.69(2H, m), 7.76 - 7.81(3H, m), 7.93(1H, m), 8.67
- 8.70(2H, m).
[0169]
Process 2: Sodium hydrogen carbonate (2.02 mg, 24.0 mmol)
was added to dimethyl sulfoxide solution (20 mL) of
hydroxylamine hydrochloride (1.42 g, 20.4 mmol) and stirred for
1 hour at 40C. Dimethyl sulfoxide solution (3 mL) of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile (430 mg,
0.987 mmol) was added to the reaction mixture and stirred for
19 hours at 90C. The reaction mixture was added water and
extracted with ethyl acetate. The organic layer was combined,
washed with water and brine, dried over anhydrous sodium sulfate,
and concentrated in vacuo. The obtained residues were
subjected to silica gel column chromatography (ethyl acetate)
to give
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
(430 mg, 93%) as a white solid.
[0170]
Process 3: 1,1’-Carbonyldiimidazole (490 mg, 3.02 mmol)
and 1,8-diazabicyclo[5.4.0]undec-7-ene (460 mg, 3.02 mmol)
were added to dimethylformamide solution (25 mL) of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
(430 mg, 0.918 mmol) and stirred for 3 hours at room temperature.
Once the reaction is completed, the reaction mixture was added
84
water and extracted with ethyl acetate. The organic layer was
combined, washed with water and brine, dried over anhydrous
sodium sulfate, and concentrated in vacuo. The obtained
residues were purified by silica gel column chromatography
(ethyl acetate) to give
3-{2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihyd
ropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-oxadiazo
l-5(4H)-one (160 mg, 35%, two step yield) as weak yellow oil.
[0171]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.42(2H, sextet, J = 8 Hz), 1.60 - 1.68(2H,
m), 2.17(3H, s), 2.64 - 2.68(2H, m), 3.93(2H, s), 7.33 - 7.56(6H,
m), 7.74 - 7.77(2H, m), 7.95(1H, dd, J = 8, 2 Hz), 8.45(1H, s),
8.67(1H, d, J = 4 Hz).
[0172]
Example 15 Preparation of
3-{2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-
oxadiazol-5(4H)-one
[0173]
[Chemical Formula 22]
85
[0174]
Process 1: By using 2-amino-4-methylpyridine instead of
2-amino-5-methoxypyrimidine in the Process 3 of the Example 1,
the reaction and the treatment were performed in the same manner
as the Process 3 of the Example 1 to give
2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1,6-
dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(yield: 61%).
[0175]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.42(2H, sextet, J = 8 Hz), 1.60 - 1.69(2H,
m), 2.17(3H, s), 2.45(3H. s), 2.66 - 2.70(2H, m), 3.96(2H, s),
7.19(1H, s), 7.24 - 7.27(2H, m), 7.48(1H, m), 7.65 - 7.69(2H,
m), 7.76 - 7.82(2H, m), 8.51(1H, d, J = 5 Hz), 8.70(1H, s).
[0176]
Process 2: By using
2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1,6-
dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
instead of
86
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1,6-
dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzim
idamide.
[0177]
Process 3: By using
2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1,6-
dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzim
idamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-methyl-1-(4-methylpyridin-2-yl)-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4-
oxadiazol-5(4H)-one (yield: 45%, two step yield) as weak yellow
oil.
[0178]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.42(2H, sextet, J = 8 Hz), 1.61 - 1.69(2H,
m), 2.17(3H, s), 2.46(3H, s), 2.65 - 2.69(2H, m), 3.94(2H, s),
7.21(1H, s), 7.24 - 7.28(2H, m), 7.37 - 7.60(3H, m), 7.78(1H,
87
dd, J = 8, 2 Hz), 7.85(1H, d, J = 7 Hz), 8.50 - 8.51(2H, m).
[0179]
Example 16 Preparation of
3-{2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one
[0180]
[Chemical Formula 23]
[0181]
Process 1: By using
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
obtained from the Process 3 of the Example 1 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
88
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxyben
zimidamide.
[0182]
Process 2: By using
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N'-hydroxyben
zimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one (yield: 48%, two step yield) as
colorless amorphous.
[0183]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.43(2H, quint, J = 8 Hz), 1.61 - 1.68(2H,
m), 2.17(3H, s), 2.65 - 2.69(2H, m), 3.95(2H, s), 4.01(3H, s),
7.36 - 7.69(4H, m), 7.76 - 7.86(2H, m), 8.51(1H, br), 8.54(2H,
s).
[0184]
Example 17 Preparation of
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one
89
[0185]
[Chemical Formula 24]
[0186]
Process 1: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
obtained from the Process 1 of the Example 2 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenz
imidamide.
[0187]
Process 2: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenz
90
imidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one (yield: 18%, two step yield) as pale
yellow amorphous.
[0188]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.38 - 1.48(2H, m), 1.51(3H, t, J = 7
Hz), 1.62 - 1.68(2H, m), 2.17(3H, s), 2.66 - 2.70(2H, m), 3.95(2H,
s), 4.22(2H, q, J = 7 Hz), 7.38 - 7.61(4H, m), 7.79(1H, d, J
= 7 Hz), 7.90(1H, d, J = 7 Hz), 8.51(2H, s), 8.54(1H, s).
[0189]
Example 18 Preparation of
3-{2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one
[0190]
[Chemical Formula 25]
91
[0191]
Process 1: By using
2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
obtained from the Process 2 of the Example 3 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenz
imidamide.
[0192]
Process 2: By using
2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenz
imidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
92
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-ethyl-1-(5-methoxypyrimidin-2-yl)-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one (yield: 53%, two step yield) as white
amorphous.
[0193]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.18(3H, t, J = 7 Hz), 1.36 - 1.50(2H,
m), 1.61 - 1.75(2H, m), 2.32(2H, q, J = 7 Hz), 2.71(2H, t, J
= 8 Hz), 3.95(2H, s), 4.00(3H, s), 4.79(1H, br s), 7.38(1H, d,
J = 8 Hz), 7.45(1H, dd, J = 8, 1 Hz), 7.51(1H, dd, J = 8, 1 Hz),
7.59(1H, td, J = 8, 2 Hz), 7.79(1H, dd, J = 8, 2 Hz), 7.89(1H,
dd, J = 8, 1 Hz), 8.52 - 8.55(3H, m).
[0194]
Example 19 Preparation of
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one
[0195]
[Chemical Formula 26]
93
[0196]
Process 1: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
obtained from the Process 1 of the Example 4 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzi
midamide.
[0197]
Process 2: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzi
midamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
94
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-ethyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one (yield: 73%, two step yield) as white
amorphous.
[0198]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.18(3H, t, J = 7 Hz), 1.34 - 1.47(2H,
m), 1.51(3H, t, J = 7 Hz), 1.60 - 1.74(2H, m), 2.32(2H, q, J
= 7 Hz), 2.70(2H, t, J = 8 Hz), 3.94(2H, s), 4.22(2H, q, J =
7 Hz), 7.36(1H, d, J = 8 Hz), 7.41 - 7.61(3H, m), 7.77(1H, dd,
J = 8, 2 Hz), 7.85(1H, dd, J = 8, 1 Hz), 8.48 - 8.53(3H, m).
[0199]
Example 20 Preparation of
3-{2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one
[0200]
[Chemical Formula 27]
95
[0201]
Process 1: By using
2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e obtained from the Process 2 of the Example 5 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide.
[0202]
Process 2: By using
2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
96
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-isopropyl-1-(5-methoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one (yield: 60%, two step yield) as white
amorphous.
[0203]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.19(6H, d, J = 7 Hz), 1.31 - 1.49(2H,
m), 1.60 - 1.75(2H, m), 2.23 - 2.35(1H, m), 2.70(2H, t, J = 8
Hz), 3.93(2H, s), 4.00(3H, s), 7.36(1H, d, J = 8 Hz), 7.43(1H,
dd, J = 7, 1 Hz), 7.49(1H, dd, J = 7, 1 Hz), 7.57(1H, td, J =
8, 1 Hz), 7.79(1H, dd, J = 8, 2 Hz), 7.85(1H, dd, J = 8, 1 Hz),
8.50(1H, d, J = 2 Hz), 8.53(2H, s).
[0204]
Example 21 Preparation of
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one
[0205]
[Chemical Formula 28]
97
[0206]
Process 1: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
obtained from the Process 1 of the Example 6 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxyb
enzimidamide.
[0207]
Process 2: By using
2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxyb
enzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
98
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one (yield: 66%, two step yield) as white
amorphous.
[0208]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.20(6H, d, J = 7 Hz), 1.36 - 1.46(2H,
m), 1.51(3H, t, J = 7 Hz), 1.62 - 1.74(2H, m), 2.23 - 2.35(1H,
m), 2.72(2H, t, J = 8 Hz), 3.94(2H, s), 4.22(2H, q, J = 7 Hz),
7.40(1H, d, J = 9 Hz), 7.46(1H, dd, J = 8, 1 Hz), 7.52(1H, td,
J = 8, 2 Hz), 7.61(1H, td, J = 8, 2 Hz), 7.82(1H, dd, J = 8,
2 Hz), 7.95(1H, dd, J = 8, 1 Hz), 8.51(2H, s), 8.58(1H, d, J
= 2 Hz).
[0209]
Example 22 Preparation of
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)
-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one
[0210]
[Chemical Formula 29]
99
[0211]
Process 1: By using
2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitr
ile obtained from the Process 2 of the Example 7 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydro
xybenzimidamide.
[0212]
Process 2: By using
2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydro
xybenzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
100
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-methoxypyrimidin-2-yl)
-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one (yield: 84%, two step yield) as
white amorphous.
[0213]
1H-NMR(CDCl3, 400 MHz):
0.81 - 0.89(2H, m), 0.93(3H, t, J = 7 Hz), 1.06 - 1.15(1H, m),
1.24(2H, t, J = 4 Hz), 1.32 - 1.44(2H, m), 1.55 - 1.67(2H, m),
2.63(2H, t, J = 8 Hz), 3.92(2H, s), 4.00(3H, s), 7.37(1H, d,
J = 8 Hz), 7.45(1H, d, J = 8 Hz), 7.51(1H, dd, J = 8, 1 Hz),
7.59(1H, td, J = 8, 1 Hz), 7.78(1H, dd, J = 8, 2 Hz), 7.89(1H,
d, J = 7 Hz), 8.52(1H, d, J = 2 Hz), 8.56(2H, s).
[0214]
Example 23 Preparation of
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one
[0215]
[Chemical Formula 30]
101
[0216]
Process 1: By using 2-amino-5-ethoxypyrimidine instead
of 2-amino-5-methoxypyridine in the Process 3 of the Example
1 and also using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclopropa
necarboxamide)-2-heptenoate instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate, the reaction and the treatment were performed in
the same manner as the Process 3 of the Example 1 to give
2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le (yield: 65%) as yellow oil.
[0217]
1H-NMR(CDCl3, 400 MHz):
0.79 - 0.87(2H, m), 0.92(3H, t, J = 8 Hz), 1.09 - 1.16(1H, m),
1.18 - 1.29(2H, m), 1.30 - 1.43(2H, m), 1.51(3H, t, J = 7 Hz),
1.54 - 1.66(2H, m), 2.61(2H, t, J = 8 Hz), 3.94(2H, s), 4.22(2H,
q, J = 7 Hz), 7.47(1H, t, J = 8 Hz), 7.57 - 7.69(2H, m), 7.71
- 7.83(3H, m), 8.54(2H, s), 8.68(1H, s).
102
[0218]
Process 2: By using
2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide.
[0219]
Process 3: By using
2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one (yield: 38%, two step yield) as
colorless crystalline powder.
103
[0220]
1H-NMR(CDCl3, 400 MHz):
0.76 - 0.87(2H, m), 0.92(3H, t, J = 7 Hz), 1.05 - 1.15(1H, m),
1.16 - 1.28(2H, m), 1.32 - 1.44(2H, m), 1.51(3H, t, J = 7 Hz),
1.54 - 1.66(2H, m), 2.61(2H, t, J = 8 Hz), 3.91(2H, s), 4.22(2H,
q, J = 7 Hz), 7.34(1H, d, J = 8 Hz), 7.38 - 7.50(2H, m), 7.51
- 7.59(1H, m), 7.71 - 7.86(2H, m), 8.46(1H, s), 8.54 (2H, s).
[0221]
Example 24 Preparation of
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one
[0222]
[Chemical Formula 31]
[0223]
Process 1: By using
2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le obtained from the Process 2 of the Example 8 instead of
104
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide.
[0224]
Process 2: By using
2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-methoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one (yield: 65%, two step yield) as
white amorphous.
[0225]
1H-NMR(CDCl3, 400 MHz):
0.96(3H, t, J = 7 Hz), 1.35 - 1.51(2H, m), 1.64 - 1.85(6H, m),
2.37 - 2.53(2H, m), 2.72(2H, t, J = 8 Hz), 3.04 - 3.20(1H, m),
3.94(2H, s), 4.00(3H, s), 7.34(1H, d, J = 8 Hz), 7.39 - 7.44(1H,
105
m), 7.44 - 7.49(1H, m), 7.51 - 7.59(1H, m), 7.74 - 7.83(2H, m),
8.48(1H, d, J = 2 Hz), 8.52(2H, s).
[0226]
Example 25 Preparation of
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one
[0227]
[Chemical Formula 32]
[0228]
Process 1: By using
2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e obtained from the Process 1 of the Example 9 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
106
2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide.
[0229]
Process 2: By using
2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-cyclobutyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one (yield: 48%, two step yield) as white
amorphous.
[0230]
1H-NMR(CDCl3, 400 MHz):
0.97(3H, t, J = 7 Hz), 1.35 - 1.47(2H, m), 1.48 - 1.83(9H, m),
2.38 - 2.52(2H, m), 2.74(2H, t, J = 8 Hz), 3.03 - 3.18(1H, m),
3.95(2H, s), 4.22(2H, q, J = 7 Hz), 7.40(1H, d, J = 8 Hz), 7.46(1H,
d, J = 8 Hz), 7.54(1H, dd, J = 8, 2 Hz), 7.61(1H, td, J = 8,
2 Hz), 7.81(1H, dd, J = 8, 2 Hz), 7.95(1H, dd, J = 8, 1 Hz),
8.49(2H, s), 8.58(1H, d, J = 2 Hz).
[0231]
Example 26 Preparation of
107
3-{2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one
[0232]
[Chemical Formula 33]
[0233]
Process 1: By using
2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le obtained from the Process 2 of the Example 10 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide.
[0234]
108
Process 2: By using
2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-cyclopentyl-1-(5-ethoxypyrimidin-2-yl)-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one (yield: 56%, two step yield) as pale
brown amorphous.
[0235]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.32 - 1.57(7H, m), 1.60 - 1.85(6H, m),
1.90 - 2.06(2H, m), 2.36 - 2.52(1H, m), 2.68(2H, t, J = 7 Hz),
3.93(2H, s), 4.22(2H, q, J = 7 Hz), 7.35(1H, d, J = 8 Hz), 7.40
- 7.60(3H, m), 7.78(1H, dd, J = 8, 2 Hz), 7.83(1H, dd, J = 8,
1 Hz), 8.49(1H, d, J = 2 Hz), 8.51(2H, s).
[0236]
Example 27 Preparation of
3-{2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one
[0237]
[Chemical Formula 34]
109
[0238]
Process 1: By using
2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e obtained from the Process 2 of the Example 11 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide.
[0239]
Process 2: By using
2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
110
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{[4-butyl-2-cyclohexyl-1-(5-ethoxypyrimidin-2-yl)-6
-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one (yield: 60%) as pale brown
amorphous.
[0240]
1H-NMR(CDCl3, 400 MHz):
0.89 - 1.07(5H, m), 1.34 - 1.94(16H, m), 2.68(2H, t, J = 8 Hz),
3.92(2H, s), 4.23(2H, q, J = 7 Hz), 7.34(1H, d, J = 8 Hz), 7.39
- 7.49(2H, m), 7.50 - 7.59(1H, m), 7.74 - 7.83(2H, m), 8.47(1H,
d, J = 2 Hz), 8.51(2H, s).
[0241]
Example 28 Preparation of
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrim
idin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2
-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one
[0242]
[Chemical Formula 35]
111
[0243]
Process 1: By using
2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrimidi
n-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2-yl
}benzonitrile obtained from the Process 1 of the Example 12
instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrimidi
n-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2-yl
}-N’-hydroxybenzimidamide.
[0244]
Process 2: By using
2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrimidi
n-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2-yl
}-N’-hydroxybenzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrim
idin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2
-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one (yield: 56%, two step
112
yield) as weak yellow oil.
[0245]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.40 - 1.46(2H, m), 1.50 - 1.70(2H, m),
2.17(3H, s), 2.24(3H, s), 2.68 - 2.71(2H, m), 2.96(2H, t, J =
7 Hz), 3.96(2H, s), 4.33(2H, t, J = 7 Hz), 7.40 - 7.62(4H, m),
7.66 - 7.97(2H, m), 8.55(2H, s), 8.58(1H, s).
[0246]
Example 29 Preparation of
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylsulfonyl)ethoxy]p
yrimidin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyrid
in-2-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one
[0247]
[Chemical Formula 36]
[0248]
By using
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylthio)ethoxy]pyrim
idin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-2
-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one obtained in the Example
113
28, the reaction and the treatment were performed in the same
manner as the Example 13 to give
3-{2-{5-{{4-butyl-2-methyl-1-{5-[2-(methylsulfonyl)ethoxy]p
yrimidin-2-yl}-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyrid
in-2-yl}phenyl}-1,2,4-oxadiazol-5(4H)-one (yield: 63%) as
colorless oil.
[0249]
1H-NMR(CDCl3, 400 MHz):
0.95(3H, t, J = 7 Hz), 1.40 - 1.46(2H, m), 1.65 - 1.70(2H, m),
2.18(3H, s), 2.67 - 2.71(2H, m), 3.09(3H, s), 3.53 - 3.55(2H,
m), 3.92(2H, s), 4.63 - 4.66(2H, m), 7.36 - 7.60(4H, m), 7.74(1H,
d, J = 8 Hz), 7.88(1H, d, J = 8 Hz), 8.59(1H, s), 8.60(2H, s).
[0250]
Example 30 Preparation of
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-2-methyl-3-(pyridin-2-yl)pyrimidin-4(3H)-one
[0251]
[Chemical Formula 37]
[0252]
114
Process 1: By using
2-[6-(bromomethyl)pyridin-3-yl]benzonitrile instead of
2-[5-(bromomethyl)pyridin-2-yl]benzonitrile in the Process 1
of the Example 1, the reaction and the treatment were performed
in the same manner as the Process 1 of the Example 1 to give
2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-3-oxoheptanoate
(yield: 69%) as yellow oil.
[0253]
1H-NMR(CDCl3, 400 MHz):
0.89(3H, t, J = 7 Hz), 1.24 - 1.34(2H, m), 1.54 - 1.61(2H, m),
2.59 - 2.76(2H, m), 3.37 - 3.55(2H, m), 3.73(3H, s), 4.37(1H,
t, J = 7 Hz), 7.33(1H, d, J = 8 Hz), 7.50(2H, t, J = 7 Hz), 7.66
- 7.70(1H, m), 7.78 - 7.83(2H, m), 8.63(1H, d, J = 2 Hz).
[0254]
Process 2: By using methyl
2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-3-oxoheptanoate
instead of methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxoheptanoate
in the Process 2 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 2 of the Example
1 to give methyl
(Z)-3-acetamide-2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-2
-heptenoate (yield: 100%) as yellow oil.
[0255]
1H-NMR(CDCl3, 400 MHz):
0.89(3H, t, J = 7 Hz), 1.27 - 1.40(2H, m), 1.47 - 1.59(2H, m),
2.24(3H, s), 3.14(2H, t, J = 8 Hz), 3.78(3H, s), 3.88(2H, s),
115
7.42 - 7.56(3H, m), 7.65 - 7.91(3H, m), 8.63(1H, s), 10.9(1H,
s).
[0256]
Process 3: By using 2-aminopyridine instead of
2-amino-5-methoxypyrimidine in the Process 3 of the Example 1
and also using methyl
(Z)-3-acetamide-2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-2
-heptenoate instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate, the reaction and the treatment were performed in
the same manner as the Process 3 of the Example 1 to give
2-{6-{[4-butyl-2-methyl-6-oxo-1-(pyrimidin-2-yl)-1,6-dihydr
opyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile (yield:
35%).
[0257]
1H-NMR(CDCl3, 400 MHz):
0.93(3H, t, J = 7 Hz), 1.42(2H, sextet, J = 8 Hz), 1.60 - 1.75(2H,
m), 2.17(3H, s), 2.74 - 2.78(2H, m), 4.17(2H, s), 7.38 - 7.50(5H,
m), 7.67(1H, m), 7.77 - 7.80(2H, m), 7.93(1H, m), 8.65(1H, d,
J = 2 Hz), 8.68(1H, d, J = 3 Hz).
[0258]
Process 4: By using
2-{6-{[4-butyl-2-methyl-6-oxo-1-(pyrimidin-2-yl)-1,6-dihydr
opyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
116
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-2-methyl-3-(pyridin-2-yl)pyrimidin-4(3H)-one (yield:
79%) as pale yellow amorphous.
[0259]
1H-NMR(CDCl3, 400 MHz):
0.89(3H, t, J = 7 Hz), 1.30 - 1.35(2H, m), 1.50 - 1.58(2H, m),
2.18(3H, s), 2.51 - 2.54(2H, m), 3.75(2H, s), 6.99(1H, d, J =
8 Hz), 7.16(1H, d, J = 8 Hz), 7.31 - 7.36(3H, m), 7.48 - 7.56(2H,
m), 7.83 - 7.87(2H, m), 7.97(1H, s), 8.56(1H, d, J = 4 Hz).
[0260]
Example 31 Preparation of
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-methoxypyridin-2-yl)-2-methylpyrimidin-4(3H)-one
[0261]
[Chemical Formula 38]
[0262]
Process 1: By using 2-amino-5-methoxypyridine instead of
117
2-amino-5-methoxypyrimidine in the Process 3 of the Example 1
and also using methyl
(Z)-3-acetamide-2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-2
-heptenoate obtained from the Process 2 of the Example 30
instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate, the reaction and the treatment were performed in
the same manner as the Process 3 of the Example 1 to give
2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
(yield: 65%) as pale yellow amorphous.
[0263]
1H-NMR(CDCl3, 400 MHz):
0.93(3H, t, J = 7 Hz), 1.37 - 1.46(2H, m), 1.58 - 1.66(2H, m),
2.18(3H, s), 2.76(2H, t, J = 8 Hz), 3.92(3H, s), 4.16(2H, s),
7.27 - 7.30(1H, m), 7.38 - 7.49(4H, m), 7.65 - 7.69(1H, m), 7.77
- 7.79(2H, m), 8.30(1H, d, J = 3 Hz), 8.65(1H, d, J = 2 Hz).
[0264]
Process 2: By using
2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
118
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-methoxypyridin-2-yl)-2-methylpyrimidin-4(3H)-one
(yield: 72%) as pale yellow amorphous.
[0265]
1H-NMR(CDCl3, 400 MHz):
0.87(3H, t, J = 7 Hz), 1.21 - 1.30(2H, m), 1.40 - 1.48(2H, m),
2.09(3H, s), 2.38(2H, t, J = 8 Hz), 3.60(2H, s), 3.90(3H, s),
7.00(1H, d, J = 8 Hz), 7.14(2H, dd, J = 8, 2 Hz), 7.20(1H, d,
J = 9 Hz), 7.34 - 7.38(2H, m), 7.53 - 7.61(2H, m), 7.84(1H, d,
J = 7 Hz), 7.90(1H, s), 8.21(1H, d, J = 3 Hz).
[0266]
Example 32 Preparation of
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylpy
rimidin-4(3H)-one
[0267]
[Chemical Formula 39]
[0268]
Process 1: By using
119
2-amino-3-chloro-5-(trifluoromethyl)pyridine instead of
2-amino-5-methoxypyrimidine in the Process 3 of the Example 1
and also using methyl
(Z)-3-acetamide-2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-2
-heptenoate obtained from the Process 2 of the Example 30
instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate, the reaction and the treatment were performed in
the same manner as the Process 3 of the Example 1 to give
2-{6-{{4-butyl-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]
-2-methyl-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-3-
yl}benzonitrile (yield: 41%) as pale yellow amorphous.
[0269]
1H-NMR(CDCl3, 400 MHz):
0.94(3H, t, J = 7 Hz), 1.37 - 1.47(2H, m), 1.57 - 1.68(2H, m),
2.16(3H, s), 2.70 - 2.83(2H, m), 4.19(2H, s), 7.38(1H, d, J =
8 Hz), 7.46 - 7.53(2H, m), 7.65 - 7.69(1H, m), 7.77 - 7.83(2H,
m), 7.89(1H, m), 8.65(1H, d, J = 2 Hz), 8.84(1H, s).
[0270]
Process 2: By using
2-{6-{{4-butyl-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]
-2-methyl-6-oxo-1,6-dihydropyrimidin-5-yl}methyl}pyridin-3-
yl}benzonitrile instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
120
1 to give
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylpy
rimidin-4(3H)-one (yield: 43%) as pale yellow amorphous.
[0271]
1H-NMR(CDCl3, 400 MHz):
0.87(3H, t, J = 7 Hz), 1.22 - 1.30(2H, m), 1.43 - 1.50(2H, m),
2.09(3H, s), 2.35 - 2.43(2H, m), 3.55(2H, dd, J = 19, 16 Hz),
6.95(1H, d, J = 8 Hz), 7.11 - 7.14(1H, m), 7.38 - 7.40(1H, m),
7.54 - 7.61(2H, m), 7.86 - 7.89(1H, m), 7.94(1H, m), 8.18(1H,
d, J = 2 Hz), 8.81(1H, s).
[0272]
Example 33 Preparation on
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
[0273]
[Chemical Formula 40]
[0274]
Process 1: By using methyl
121
(Z)-3-acetamide-2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-2
-heptenoate obtained from the Process 2 of the Example 30
instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate in the Process 3 of the Example 1, the reaction and
the treatment were performed in the same manner as the Process
3 of the Example 1 to give
2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
(yield: 51%) as pale yellow amorphous.
[0275]
1H-NMR(CDCl3, 400 MHz):
0.93(3H, t, J = 7 Hz), 1.36 - 1.45(2H, m), 1.57 - 1.65(2H, m),
2.16(3H, s), 2.75(2H, t, J = 8 Hz), 4.00(3H, s), 4.17(2H, s),
7.40 - 7.49(3H, m), 7.64 - 7.69(1H, m), 7.77 - 7.79(2H, m),
8.54(2H, s), 8.65(1H, d, J = 2 Hz).
[0276]
Process 2: By using
2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
122
tyl-3-(5-methoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
(yield: 52%) as pale yellow amorphous.
[0277]
1H-NMR(CDCl3, 400 MHz):
0.86(3H, t, J = 7 Hz), 1.20 - 1.29(2H, m), 1.41 - 1.49(2H, m),
2.09(3H, s), 2.43(2H, t, J = 8 Hz), 3.62(2H, s), 3.98(3H, s),
7.00(1H, d, J = 8 Hz), 7.13(1H, dd, J = 8, 2 Hz), 7.39(1H, d,
J = 8 Hz), 7.51 - 7.60(2H, m), 7.84(1H, d, J = 8 Hz), 7.95(1H,
d, J = 2 Hz), 8.48(2H, s).
[0278]
Example 34 Preparation of
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
[0279]
[Chemical Formula 41]
[0280]
Process 1: By using 2-amino-5-ethoxypyrimidine instead
of 2-amino-5-methoxypyrimidine in the Process 3 of the Example
1 and also using methyl
123
(Z)-3-acetamide-2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-2
-heptenoate obtained from the Process 2 of the Example 30
instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate, the reaction and the treatment were performed in
the same manner as the Process 3 of the Example 1 to give
2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
(yield: 70%) as pale yellow amorphous.
[0281]
1H-NMR(CDCl3, 400 MHz):
0.92(3H, t, J = 7 Hz), 1.36 - 1.45(2H, m), 1.51(3H, t, J = 7
Hz), 1.57 - 1.65(2H, m), 2.16(3H, s), 2.75(2H, t, J = 8 Hz),
4.18(2H, s), 4.22(2H, q, J = 7 Hz), 7.41 - 7.52(3H, m), 7.64
- 7.68(1H, m), 7.77 - 7.81(2H, m), 8.52(2H, s), 8.63 - 8.65(1H,
m).
[0282]
Process 2: By using
2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
124
tyl-3-(5-ethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)-one
(yield: 63%) as yellow amorphous.
[0283]
1H-NMR(CDCl3, 400 MHz):
0.86(3H, t, J = 7 Hz), 1.18 - 1.29(2H, m), 1.40 - 1.50(2H, m),
1.49(3H, t, J = 7 Hz), 2.09(3H, s), 2.42(2H, t, J = 8 Hz), 3.61(2H,
s), 4.20(q, 2H, J = 7 Hz), 7.00(1H, d, J = 8 Hz), 7.12(1H, dd,
J = 8, 2 Hz), 7.39(1H, d, J = 8 Hz), 7.51 - 7.61(2H, m), 7.86(1H,
d, J = 7 Hz), 7.74(1H, d, J = 2 Hz), 8.46(2H, s).
[0284]
Example 35 Preparation of
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
tyl-3-(4,6-dimethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)
-one
[0285]
[Chemical Formula 42]
[0286]
Process 1: By using 2-amino-4,6-dimethoxypyrimidine
instead of 2-amino-5-methoxypyrimidine in the Process 3 of the
125
Example 1 and also using methyl
(Z)-3-acetamide-2-{[5-(2-cyanophenyl)pyridin-2-yl]methyl}-2
-heptenoate obtained from the Process 2 of the Example 30
instead of methyl
(Z)-3-acetamide-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2
-heptenoate, the reaction and the treatment were performed in
the same manner as the Process 3 of the Example 1 to give
2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitri
le (yield: 49%) as pale yellow amorphous.
[0287]
1H-NMR(CDCl3, 400 MHz):
0.93(3H, t, J = 7 Hz), 1.38 - 1.47(2H, m), 1.56 - 1.67(2H, m),
2.24(3H, s), 2.76(2H, t, J = 8 Hz), 3.96(6H, s), 4.19(2H, s),
6.12(1H, s), 7.45 - 7.50(3H, m), 7.65 - 7.69(1H, m), 7.77 -
7.82(2H, m), 8.66(1H, d, J = 2 Hz).
[0288]
Process 2: By using
2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitri
le instead of
2-{5-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
in the Process 4 of the Example 1, the reaction and the treatment
were performed in the same manner as the Process 4 of the Example
1 to give
5-{{5-[2-(1H-tetrazol-5-yl)phenyl]pyridin-2-yl}methyl}-6-bu
126
tyl-3-(4,6-dimethoxypyrimidin-2-yl)-2-methylpyrimidin-4(3H)
-one (yield: 53%) as pale yellow amorphous.
[0289]
1H-NMR(CDCl3, 400 MHz):
0.88(3H, t, J = 7 Hz), 1.22 - 1.32(2H, m), 1.43 - 1.50(2H, m),
2.17(3H, s), 2.42(2H, t, J = 8 Hz), 3.62(2H, s), 3.89(6H, s),
6.06(1H, s), 7.02(1H, d, J = 8 Hz), 7.14(1H, dd, J = 8, 2 Hz),
7.40(1H, d, J = 8 Hz), 7.53 - 7.62(2H, m), 7.31(1H, d, J = 8
Hz), 7.95(1H, s).
[0290]
Example 36 Preparation on
3-{2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one
[0291]
[Chemical Formula 43]
[0292]
Process 1: By using
2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-1,6
127
-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
obtained from the Process 1 of the Example 31 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydroxybenzi
midamide (yield: 64%) as pale yellow amorphous.
[0293]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.34 - 1.43(2H, m), 1.54 - 1.62(2H, m),
2.16(3H, s), 2.71(2H, t, J = 8 Hz), 3.91(3H, s), 4.13(2H, s),
4.50(2H, s), 7.29 - 7.42(5H, m), 7.45 - 7.49(1H, m), 7.55 -
7.57(1H, m), 7.66 - 7.69(1H, m), 8.29(1H, d, J = 3 Hz), 8.60(1H,
d, J = 2 Hz).
[0294]
Process 2: By using
2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-1,6
-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydroxybenzi
midamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
128
3-{2-{6-{[4-butyl-1-(5-methoxypyridin-2-yl)-2-methyl-6-oxo-
1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,4
-oxadiazol-5(4H)-one (yield: 70%) as pale yellow amorphous.
[0295]
1H-NMR(CDCl3, 400 MHz):
0.92(3H, t, J = 7 Hz), 1.30 - 1.39(2H, m), 1.49 - 1.57(2H, m),
2.11(3H, s), 2.51(2H, t, J = 8 Hz), 3.62(2H, s), 3.91(3H, s),
7.15(1H, d, J = 8 Hz), 7.23(2H, d, J = 9 Hz), 7.32 - 7.39(2H,
m), 7.48 - 7.52(2H, m), 7.57 - 7.61(1H, m), 7.70(1H, d, J = 8
Hz), 7.99(1H, s), 8.18(1H, d, J = 3 Hz).
[0296]
Example 37 Preparation of
3-{2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one
[0297]
[Chemical Formula 44]
[0298]
Process 1: By using
2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
129
,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
obtained from the Process 1 of the Example 33 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydroxyben
zimidamide (yield: 50%) as pale yellow amorphous.
[0299]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.34 - 1.43(2H, m), 1.54 - 1.62(2H, m),
2.15(3H, s), 2.73(2H, t, J = 8 Hz), 3.99(3H, s), 4.13(2H, s),
4.50(2H, s), 7.28 - 7.42(3H, m), 7.45 - 7.49(1H, m), 7.53 -
7.57(1H, m), 7.66 - 7.69(1H, m), 8.53(2H, s), 8.59(1H, d, J =
2 Hz).
[0300]
Process 2: By using
2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-oxo-1
,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydroxyben
zimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
14 to give
130
3-{2-{6-{[4-butyl-1-(5-methoxypyrimidin-2-yl)-2-methyl-6-ox
o-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2
,4-oxadiazol-5(4H)-one (yield: 85%) as pale yellow amorphous.
[0301]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.27 - 1.36(2H, m), 1.45 - 1.53(2H, m),
2.11(3H, s), 2.45(2H, t, J = 8 Hz), 3.56(2H, s), 4.00(3H, s),
7.12(1H, d, J = 8Hz), 7.38(1H, d, J = 8 Hz), 7.50 - 7.60(2H,
m), 7.60 - 7.64(1H, m), 7.72(1H, d, J = 1 Hz), 7.90(1H, s),
8.51(2H, s).
[0302]
Example 38 Preparation of
3-{2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one
[0303]
[Chemical Formula 45]
[0304]
Process 1: By using
131
2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitrile
obtained from the Process 1 of the Example 34 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydroxybenz
imidamide (yield: 52%) as pale yellow amorphous.
[0305]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.35 - 1.43(2H, m), 1.50(3H, t, J = 7
Hz), 1.51 - 1.62(2H, m), 2.15(3H, s), 2.72(2H, t, J = 8 Hz),
4.13(2H, s), 4.21(2H, q, J = 7 Hz), 4.51(2H, s), 7.28 - 7,49(4H,
m), 7.55 - 7.57(1H, m), 7.66 - 7.69(1H, m), 8.50(2H, s), 8.59
- 8.60(1H, m).
[0306]
Process 2: By using
2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydroxybenz
imidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
132
14 to give
3-{2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}-1,2,
4-oxadiazol-5(4H)-one (yield: 89%) as pale yellow amorphous.
[0307]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7 Hz), 1.27 - 1.36(2H, m), 1.45 - 1.52(5H, m),
2.11(3H, s), 2.49(2H, t, J = 8 Hz), 3.59(2H, s), 4.22(2H, q,
J = 7 Hz), 7.18(1H, d, J = 8 Hz), 7.38(1H, d, J = 8 Hz), 7.50
- 7.55(2H, m), 7.60 - 7.64(1H, m), 7.72(1H, d, J = 8 Hz), 7.93
- 7.97(1H, m), 8.49(2H, s).
[0308]
Example 39 Preparation of
3-{2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one
[0309]
[Chemical Formula 46]
[0310]
133
Process 1: By using
2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}benzonitri
le in the Process 1 of the Example 35 instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile in the
Process 2 of the Example 14, the reaction and the treatment were
performed in the same manner as the Process 2 of the Example
14 to give
2-{6-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-2-methyl-6-oxo-1,
6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydroxybenz
imidamide (yield: 47%) as pale yellow amorphous.
[0311]
1H-NMR(CDCl3, 400 MHz):
0.92(3H, t, J = 7 Hz), 1.36 - 1.45(2H, m), 1.56 - 1.64(2H, m),
2.23(3H, s), 2.73(2H, t, J = 8 Hz), 3.95(6H, s), 4.14(2H, s),
4.49(2H, s), 6.12(1H, s), 7.32 - 7.43(3H, m), 7.46 - 7.50(1H,
m), 7.56 - 7.58(1H, m), 7.69 - 7.71(1H, m), 8.57 - 8.61(1H, m).
[0312]
Process 2: By using
2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}-N’-hydrox
ybenzimidamide instead of
2-{5-{[4-butyl-2-methyl-6-oxo-1-(pyridin-2-yl)-1,6-dihydrop
yrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxybenzimidamide
in the Process 3 of the Example 14, the reaction and the treatment
were performed in the same manner as the Process 3 of the Example
134
14 to give
3-{2-{6-{[4-butyl-1-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-3-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one (yield: 52%) as pale yellow
amorphous.
[0313]
1H-NMR(CDCl3, 400 MHz):
0.92(3H, t, J = 7 Hz), 1.31 - 1.40(2H, m), 1.50 - 1.58(2H, m),
2.18(3H, s), 2.51(2H, t, J = 8 Hz), 3.67(2H, s), 3.92(6H, s),
6.08(1H, s), 7.21(1H, d, J = 8 Hz), 7.41(1H, d, J = 8 Hz), 7.50
- 7.56(2H, m), 7.63(1H, t, J = 8 Hz), 7.74(1H, d, J = 8 Hz),
8.01(1H, d, J = 2 Hz).
[0314]
Example 40 Preparation of
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one
[0315]
[Chemical Formula 47]
135
[0316]
Process 1: Under argon atmosphere, tetrahydrofuran (20
mL) mixture containing
2-[5-(bromomethyl)pyridin-2-yl]benzonitrile (1.1 g, 3.9 mmol),
methyl 3-oxohexanoate (0.68 g, 4.7 mmol),
diisopropylethylamine (1.0 g, 7.8 mmol), and lithium bromide
monohydrate (0.49 g, 4.7 mmol) was refluxed under heating for
18 hours. The reaction mixture was added water and extracted
three times with chloroform. The organic layer was combined,
washed with water and brine, dried over anhydrous sodium sulfate,
and concentrated in vacuo. The obtained residues were
subjected to silica gel column chromatography (SNAP100HP
manufactured by Biotage) (hexane/ethyl acetate; 5/11/1) to
give methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxohexanoate
(1.2 g, 91%) as yellow oil.
[0317]
1H-NMR(CDCl3, 400 MHz):
0.87(3H, t, J = 7.4 Hz), 1.50 - 1.55(2H, m), 2.36 - 2.68(2H,
m), 3.21 - 3.27(2H, m), 3.73(3H, s), 3.84(1H, t, J = 7.6 Hz),
7.50(1H, td, J = 7.6, 1.4 Hz), 7.64 - 7.73(3H, m), 7.77 - 7.85(2H,
m), 8.61(1H, br s).
[0318]
Process 2: A toluene (45 mL)-acetic acid (5 mL) mixture
containing methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxohexanoate
(1.2 g, 3.6 mmol) and ammonium acetate (8.3 g, 108 mmol) was
136
refluxed under heating for 1 hour. After cooling to room
temperature, saturated aqueous solution of sodium hydrogen
carbonate was added and extraction was carried out with toluene.
After washing with brine, it was dried over anhydrous sodium
sulfate and concentrated in vacuo to give methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2-hex
enoate (1.15 g) as brown oil crude product. It was used for
the next process without purification.
[0319]
Process 3: Isobutyryl chloride (219 mg, 2.06 mmol) and
triethylamine (208 mg, 2.06 mmol) were added to
1,2-dichloroethane (10 mL) solution of methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-2-hex
enoate (575 mg) and stirred for 16 hours at 50C. The reaction
mixture was added water and extracted with chloroform. The
organic layer was combined, washed with brine, dried over
anhydrous sodium sulfate, and concentrated in vacuo. The
obtained residues were subjected to silica gel column
chromatography (SNAP50HP manufactured by Biotage)
(hexane/ethyl acetate; 5/11/1) to give methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-hexenoate (158 mg, 23%; two step yield) as black oil.
[0320]
1H-NMR(CDCl3, 400 MHz):
0.99(3H, t, J = 7.4 Hz), 1.19 - 1.29(8H, m), 2.49 - 2.62(1H,
m), 2.88 - 2.97(2H, m), 3.71(3H, s), 3.76(2H, s), 7.51(1H, dd,
J = 7.6, 1.3 Hz), 7.59(1H, dd, J = 8.1, 2.1 Hz), 7.64 - 7.73(2H,
137
m), 7.77 - 7.86(2H, m), 8.60(1H, s), 11.90(1H, s).
[0321]
Process 4: Under argon atmosphere, trimethylaluminum (2
mol/L hexane solution, 0.39 mL, 0.78 mmol) was added to
1,2-dichloroethane (5 mL) solution of
2-amino-5-ethoxypyrimidine (108 mg, 0.78 mmol) at room
temperature and stirred for 70 minutes at room temperature.
1,2-dichloroethane solution (2 mL) of methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-hexenoate (158 mg, 0.39 mmol) was added dropwise thereto
at room temperature and refluxed under heating for 3 hours. The
reaction mixture was added an aqueous solution of ammonium
chloride and chloroform, and filtered through a pad of celite.
The organic layer in the filtrate was separated and the aqueous
layer was extracted with chloroform. The organic layer was
combined, washed with water and brine, dried over anhydrous
sodium sulfate, and concentrated in vacuo. The obtained
residues were subjected to silica gel column chromatography
(Flash12M manufactured by Biotage) (chloroform/methanol = 40 :
1) to give
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e (111 mg, 58%) as yellow oil.
[0322]
1H-NMR(CDCl3, 400 MHz):
0.97(3H, t, J = 7.4 Hz), 1.17(6H, d, J = 6.6 Hz), 1.49(3H, t,
J = 6.9 Hz), 1.66 - 1.77(2H, m), 2.19 - 2.32(1H, m), 2.60 - 2.70(2H,
138
m), 3.93(2H, s), 4.10(2H, q, J = 7.1 Hz), 7.45(1H, td, J = 7.7,
1.1 Hz), 7.60 - 7.67(2H, m), 7.73 - 7.80(3H, m), 8.49(2H, s),
8.67(1H, d, J = 1.3 Hz).
[0323]
Process 5: Sodium hydrogen carbonate (1.19 g, 14.1 mmol)
was added to dimethyl sulfoxide (15 mL) mixture of hydroxylamine
hydrochloride (838 mg, 12.1 mmol) and stirred for 1 hour at 40C.
The reaction mixture was added dimethyl sulfoxide (15 mL)
solution of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e (353 mg, 0.71 mmol) and stirred for 18 hours at 90C. The
reaction mixture was added water (80 mL) and ethyl acetate (20
mL) and stirred for 30 minutes. The precipitated solid was
collected by filtration and washed with water and ethyl acetate.
It was then dried in vacuo to give
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide (214 mg, 57%) as a white solid.
[0324]
1H-NMR(CDCl3, 400 MHz):
0.98(3H, t, J = 7.3 Hz), 1.19(6H, d, J = 6.6 Hz), 1.51(3H, t,
J = 7.0 Hz), 1.68 - 1.78(2H, m), 2.25 - 2.32(1H, m), 2.63 - 2.70(2H,
m), 3.92(2H, s), 4.22(2H, q, J = 6.9 Hz), 4.72(2H, br s), 7.40(1H,
td, J = 7.5, 1.3 Hz), 7.43(1H, d, J = 8.5 Hz), 7.49(1H, td, J
= 7.6, 1.5 Hz), 7.55(1H, dd, J = 7.6, 1.2 Hz), 7.58(1H, dd, J
= 7.8, 1.2 Hz), 7.66(1H, dd, J = 8.2, 2.3 Hz), 8.51(2H, s),
139
8.60(1H, d, J = 1.7 Hz).
[0325]
Process 6: 1,1’-Carbonyldiimidazole (130 mg, 0.80 mmol)
and 1,8-diazabicyclo[5.4.0]undeca-7-ene (122 mg, 0.80 mmol)
were added to dichloromethane (4 mL) and tetrahydrofuran (4 mL)
mixture solution of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide (212 mg, 0.40 mmol) and stirred for 3 hours at
room temperature. Once the reaction is completed, 1 M
hydrochloric acid solution was added to the reaction mixture,
which was then extracted with chloroform. The organic layer
was washed with water, dried over anhydrous sodium sulfate, and
concentrated in vacuo. The obtained residues were subjected
to silica gel column chromatography (chloroform/methanol = 20 :
1) to give
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pr
opyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one (201 mg, 91%) as white amorphous.
[0326]
1H-NMR(CDCl3, 400 MHz):
1.01(3H, t, J = 7.3 Hz), 1.19(6H, d, J = 6.6 Hz), 1.51(3H, t,
J = 7.0 Hz), 1.71 - 1.82(2H, m), 2.26 - 2.32(1H, m), 2.66 - 2.73(2H,
m), 3.95(2H, s), 4.22(2H, q, J = 7.0 Hz), 7.39(1H, d, J = 8.1
Hz), 7.45(1H, d, J = 8.1 Hz), 7.51(1H, t, J = 7.6 Hz), 7.60(1H,
t, J = 7.7 Hz), 7.83(1H, dd, J = 8.1, 1.7 Hz), 7.93(1H, d, J
= 7.8 Hz), 8.51(2H, s), 8.56(1H, s).
140
[0327]
Example 41 Preparation of
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one
[0328]
[Chemical Formula 48]
[0329]
Process 1: By using cyclopropylcarbonyl chloride instead
of isobutyryl chloride in the Process 3 of the Example 40, the
reaction and the treatment were performed in the same manner
as the Process 3 of the Example 40 to give methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-cyclopropan
ecarboxyamide-2-hexenoate (yield: 58%).
[0330]
1H-NMR(CDCl3, 400 MHz):
0.83 - 1.10(8H, m), 1.58 - 1.62(2H, m), 2.87 - 2.96(2H, m),
3.71(3H, s), 3.76(2H, s), 7.49(1H, td, J = 7.6, 1.3 Hz), 7.58(1H,
dd, J = 8.1, 2.1 Hz), 7.65 - 7.72(2H, m), 7.77 - 7.86(2H, m),
141
8.61(1H, s), 12.15(1H, s).
[0331]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-(cyclopropa
necarboxyamide)-2-hexenoate instead of methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-hexenoate in the Process 4 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 4 of the Example 40 to give
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pro
pyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitr
ile (yield: 58%).
[0332]
1H-NMR(CDCl3, 400 MHz):
0.80 - 0.87(2H, m), 0.96(3H, t, J = 7.5 Hz), 1.08 - 1.14(1H,
m), 1.21 - 1.25(2H, m), 1.51(3H, t, J = 7.0 Hz), 1.61 - 1.72(2H,
m), 2.57 - 2.61(2H, m), 3.94(2H, s), 4.22(2H, q, J = 6.9 Hz),
7.47(1H, td, J = 7.6, 1.1 Hz), 7.63 - 7.69(2H, m), 7.74 - 7.82(3H,
m), 8.54(2H, s), 8.68(1H, d, J = 1.8 Hz).
[0333]
Process 3: By using
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pro
pyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitr
ile instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e in the Process 5 of the Example 40, the reaction and the
142
treatment were performed in the same manner as the Process 5
of the Example 40 to give
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pro
pyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydro
xybenzimidamide (yield: 67%).
[0334]
1H-NMR(CDCl3, 400 MHz):
0.79 - 0.88(2H, m), 0.94(3H, t, J = 7.4 Hz), 1.06 - 1.15(1H,
m), 1.19 - 1.26(2H, m), 1.51(3H, t, J = 7.1 Hz), 1.59 - 1.71(2H,
m), 2.53 - 2.64(2H, m), 3.91(2H, s), 4.22(2H, q, J = 7.0 Hz),
4.73(2H, s), 7.40(1H, td, J = 7.3, 1.6 Hz), 7.43(1H, d, J = 7.6
Hz), 7.49(1H, td, J = 7.6, 1.5 Hz), 7.55(1H, dd, J = 7.6, 1.0
Hz), 7.58(1H, dd, J = 7.7, 0.9 Hz), 7.64(1H, dd, J = 8.2, 2.3
Hz), 8.54(2H, s), 8.59(1H, d, J = 2.2 Hz).
[0335]
Process 4: By using
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pro
pyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydro
xybenzimidamide instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide in the Process 6 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 6 of the Example 40 to give
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one (yield: 94%) as white amorphous.
143
[0336]
1H-NMR(CDCl3, 400 MHz):
0.81 - 0.89(1H, m), 0.97(3H, t, J = 7.4 Hz), 1.06 - 1.15(1H,
m), 1.21 - 1.27(2H, m), 1.51(3H, t, J = 7.0 Hz), 1.66 - 1.70(2H,
m), 2.61(2H, t, J = 7.4 Hz), 3.94(2H, s), 4.22(2H, q, J = 6.8
Hz), 7.39(1H, d, J = 8.3 Hz), 7.45(1H, d, J = 7.6 Hz), 7.52(1H,
t, J = 7.6 Hz), 7.60(1H, t, J = 7.2 Hz), 7.81(1H, dd, J = 7.9,
1.8 Hz), 7.94(1H, d, J = 7.8 Hz), 8.54(2H, s), 8.55(1H, s).
[0337]
Example 42 Preparation of
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one
[0338]
[Chemical Formula 49]
[0339]
Process 1: By using methyl 3-oxooctanoate instead of
methyl 3-oxohexanoate in the Process 1 of the Example 40, the
reaction and the treatment were performed in the same manner
144
as the Process 1 of the Example 40 to give methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxooctanoate
(yield: 88%).
[0340]
1H-NMR(CDCl3, 400 MHz):
0.86(3H, t, J = 6.9 Hz), 1.19 - 1.32(4H, m), 1.49 - 1.55(2H,
m), 2.35 - 2.67(2H, m), 3.20 - 3.26(2H, m), 3.73(3H, s), 3.84(1H,
t, J = 7.4 Hz), 7.50(1H, td, J = 7.6, 1.3 Hz), 7.64 - 7.73(3H,
m), 7.77 - 7.85(2H, m), 8.61(1H, br s).
[0341]
Process 2: By using methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxooctanoate
instead of methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxohexanoate in
the Process 2 of the Example 40, the reaction and the treatment
were performed in the same manner as the Process 2 of the Example
40 to give methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}octeno
ate (yield: 82%) as brown oil crude product. It was used for
the next process without purification.
[0342]
Process 3: By using methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}octeno
ate instead of methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}hexeno
ate in the Process 3 of the Example 40, the reaction was performed
in the same manner as the Process 3 of the Example 40. According
145
to a post-treatment carried out in the same manner as the Process
3 of the Example 40, methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-octenoate was obtained as a crude product. It was used
for the next process without purification.
[0343]
Process 4: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-octenoate instead of methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-hexenoate in the Process 4 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 4 of the Example 40 to give
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-penty
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e (yield: 86%).
[0344]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 6.8 Hz), 1.20(6H, d, J = 6.8 Hz), 1.32 - 1.39(4H,
m), 1.51(3H, t, J = 7.0 Hz), 1.65 - 1.75(2H, m), 2.24 - 2.33(1H,
m), 2.65 - 2.71(2H, m), 3.95(2H, s), 4.22(2H, q, J = 7.0 Hz),
7.47(1H, td, J = 7.6, 1.1 Hz), 7.63 - 7.69(2H, m), 7.76 - 7.82(3H,
m), 8.51(2H, s), 8.70(1H, d, J = 1.5 Hz).
[0345]
Process 5: By using
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-penty
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
146
e instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e in the Process 5 of the Example 40, the reaction and the
treatment were performed in the same manner as the Process 5
of the Example 40 to give
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-penty
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide (yield: 59%).
[0346]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7.0 Hz), 1.21(6H, t, J = 12.2 Hz), 1.30 - 1.39(4H,
m), 1.51(3H, t, J = 7.0 Hz), 1.65 - 1.74(2H, m), 2.25 - 2.32(1H,
m), 2.68(2H, t, J = 7.6 Hz), 3.92(2H, s), 4.22(2H, q, J = 7.0
Hz), 4.73(2H, br s), 7.40(1H, td, J = 7.6, 1.4 Hz), 7.43(1H,
d, J = 8.5 Hz), 7.49(1H, td, J = 7.5, 1.3 Hz), 7.55(1H, dd, J
= 7.6, 1.2 Hz), 7.58(1H, dd, J = 7.6, 1.2 Hz), 7.66(1H, dd, J
= 8.2, 2.3 Hz), 8.51(2H, s), 8.59(1H, d, J = 2.0 Hz).
[0347]
Process 6: By using
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-penty
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide in the Process 6 of the Example 40, the reaction
and the treatment were performed in the same manner as the
147
Process 6 of the Example 40 to give
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-pe
ntyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-
1,2,4-oxadiazol-5(4H)-one (yield: 99%).
[0348]
1H-NMR(CDCl3, 400 MHz):
0.90(3H, t, J = 7.0 Hz), 1.20(6H, d, J = 6.6 Hz), 1.31 - 1.42(4H,
m), 1.51(3H, t, J = 7.1 Hz), 1.67 - 1.77(2H, m), 2.26 - 2.32(1H,
m), 2.71(2H, t, J = 7.6 Hz), 3.95(2H, s), 4.22(2H, q, J = 7.0
Hz), 7.41(1H, d, J = 8.1 Hz), 7.45(1H, dd, J = 7.8, 1.2 Hz),
7.53(1H, td, J = 7.7, 1.2 Hz), 7.61(1H, td, J = 7.6, 1.5 Hz),
7.84(1H, d, J = 8.3 Hz), 7.97(1H, d, J = 7.6 Hz), 8.51(2H, s),
8.59(1H, s).
[0349]
Example 43 Preparation of
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one
[0350]
[Chemical Formula 50]
148
[0351]
Process 1: By using cyclopropylcarbonyl chloride instead
of isobutyryl chloride in the Process 3 of the Example 40 and
also using methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}octeno
ate instead of methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}hexeno
ate, the reaction was performed in the same manner as the Process
3 of the Example 40. According to a post-treatment carried out
in the same manner as the Process 3 of the Example 40, methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-cyclopropan
ecarboxamide-2-octenoate was obtained as a crude product. It
was used for the next process without purification.
[0352]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-cyclopropan
ecarboxamide-2-octenoate instead of methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-hexenoate in the Process 4 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 4 of the Example 40 to give
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pen
tyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitr
ile (yield: 64%).
[0353]
1H-NMR(CDCl3, 400 MHz):
0.81 - 0.91(5H, m), 1.07 - 1.14(1H, m), 1.21 - 1.26(2H, m), 1.29
149
- 1.36(4H, m), 1.49 - 1.53(3H, m), 1.60 - 1.65(2H, m), 2.57 -
2.63(2H, m), 3.94(2H, s), 4.22(2H, q, J = 7.1 Hz), 7.44 - 7.50(1H,
m), 7.63 - 7.69(2H, m), 7.73 - 7.83(3H, m), 8.54(2H, s), 8.69(1H,
s).
[0354]
Process 3: By using
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pen
tyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitr
ile instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e in the Process 5 of the Example 40, the reaction and the
treatment were performed in the same manner as the Process 5
of the Example 40 to give
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pen
tyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydro
xybenzimidamide (yield: 70%).
[0355]
1H-NMR(CDCl3, 400 MHz):
0.81 - 0.86(2H, m), 0.89(3H, t, J = 6.8 Hz), 1.06 - 1.15(1H,
m), 1.19 - 1.25(2H, m), 1.28 - 1.35(4H, m), 1.51(3H, t, J = 7.1
Hz), 1.58 - 1.65(2H, m), 2.60(2H, t, J = 7.9 Hz), 3.90(2H, s),
4.22(2H, q, J = 7.0 Hz), 4.73(2H, br s), 7.40(1H, td, J = 7.5,
1.5 Hz), 7.43(1H, d, J = 7.8 Hz), 7.49(1H, td, J = 7.6, 1.5 Hz),
7.55(1H, dd, J = 7.6, 1.5 Hz), 7.58(1H, dd, J = 7.9, 1.1 Hz),
7.64(1H, dd, J = 8.1, 2.4 Hz), 8.54(2H, s), 8.58(1H, d, J = 1.7
Hz).
150
[0356]
Process 4: By using
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-pen
tyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydro
xybenzimidamide instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide in the Process 6 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 6 of the Example 40 to give
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-oxo-4-
pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl
}-1,2,4-oxadiazol-5(4H)-one (yield: 91%) as white amorphous.
[0357]
1H-NMR(CDCl3, 400 MHz):
0.82 - 0.93(5H, m), 1.07 - 1.15(1H, m), 1.21 - 1.27(2H, m), 1.29
- 1.38(4H, m), 1.51(3H, t, J = 7.0 Hz), 1.59 - 1.70(2H, m),
2.62(2H, t, J = 7.7 Hz), 3.93(2H, s), 4.22(2H, q, J = 7.0 Hz),
7.40(1H, d, J = 7.8 Hz), 7.45(1H, d, J = 7.6 Hz), 7.53(1H, td,
J = 7.6, 1.2 Hz), 7.61(1H, td, J = 7.7, 1.4 Hz), 7.81(1H, dd,
J = 7.9, 2.1 Hz), 7.96(1H, d, J = 7.8 Hz), 8.54(2H, s), 8.57(1H,
s), 7.60(1H, t, J = 7.2 Hz), 7.81(1H, dd, J = 7.9, 1.8 Hz), 7.94(1H,
d, J = 7.8 Hz), 8.54(2H, s), 8.55(1H, s).
[0358]
Example 44 Preparation of
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
151
,2,4-oxadiazol-5(4H)-one
[0359]
[Chemical Formula 51]
[0360]
Process 1: By using methyl 3-oxopentanoate instead of
methyl 3-oxohexanoate in the Process 1 of the Example 40, the
reaction and the treatment were performed in the same manner
as the Process 1 of the Example 40 to give
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxopentanoate
(yield: 43%).
[0361]
1H-NMR(CDCl3, 400 MHz):
1.05(3H, t, J = 7 Hz), 2.44(1H, dq, J = 22, 7 Hz), 2.66(1H, dq,
J = 22, 7 Hz), 3.24(2H, dd, J = 7, 7 Hz), 3.73(3H, s), 3.84(1H,
t, J = 7 Hz), 7.50(1H, dd, J = 8, 1 Hz), 7.67 - 7.70(3H, m),
7.78(1H, d, J = 8 Hz), 7.83(1H, d, J = 8 Hz), 8.60(1H, d, J =
2 Hz).
[0362]
Process 2: By using methyl
152
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxopentanoate
instead of methyl
2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-oxohexanoate in
the Process 2 of the Example 40, the reaction and the treatment
were performed in the same manner as the Process 2 of the Example
40 to give methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}penten
oate as a crude product. It was used for the next process
without purification.
[0363]
Process 3: By using methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}penten
oate instead of methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}hexeno
ate in the Process 3 of the Example 40, the reaction was performed
in the same manner as the Process 3 of the Example 40. According
to a post-treatment carried out in the same manner as the Process
3 of the Example 40, methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-pentenoate (two step yield: 3.3%) was obtained as a crude
product.
[0364]
1H-NMR(CDCl3, 400 MHz):
1.17(3H, t, J = 7 Hz), 1.25(6H, d, J = 7 Hz), 2.57(1H, sept,
J = 7 Hz), 3.0(2H, q, J = 7 Hz), 3.71(3H, s), 3.77(2H, s), 7.49(1H,
dd, J = 8, 1 Hz), 7.60(1H, dd, J = 8, 2 Hz), 7.70(2H, m), 7.79(1H,
d, J = 8 Hz), 7.83(1H, d, J = 8 Hz), 8.61(1H, d, J = 2 Hz), 11.9(1H,
153
s).
[0365]
Process 4: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-pentenoate instead of methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-hexenoate in the Process 4 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 4 of the Example 40 to give
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
(yield: 58%).
[0366]
1H-NMR(CDCl3, 400 MHz):
1.20(6H, d, J = 7 Hz), 1.25(3H, t, J = 8 Hz), 1.52(3H, t, J =
7 Hz), 2.29(1H, sept, J = 7 Hz), 2.72(2H, q, J = 8 Hz), 4.0(2H,
s), 4.21(2H, q, J = 7 Hz), 7.47(1H, dd, J = 8, 1 Hz), 7.64 -
7.68(2H, m), 7.76 - 7.78(3H, m), 8.51(2H, s), 8.70(1H, d, J =
2 Hz).
[0367]
Process 5: By using
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitrile
instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e in the Process 5 of the Example 40, the reaction and the
154
treatment were performed in the same manner as the Process 5
of the Example 40 to give
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxyb
enzimidamide (yield: 61%).
[0368]
1H-NMR(CDCl3, 400 MHz):
1.19(6H, d, J = 7 Hz), 1.22(3H, t, J = 8 Hz), 1.50(3H, t, J =
7 Hz), 2.29(1H, sept, J = 7 Hz), 2.69(2H, q, J = 8 Hz), 3.91(2H,
s), 4.20(2H, q, J = 7 Hz), 4.78(2H, br), 7.37 - 7.40(2H, m),
7.44 - 7.51(2H, m), 7.56(1H, dd, J = 8, 1 Hz), 7.63(1H, dd, J
= 8, 2 Hz), 8.50(2H, s), 8.57(1H, d, J = 2 Hz).
[0369]
Process 6: By using
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-oxo
-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxyb
enzimidamide instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide in the Process 6 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 6 of the Example 40 to give
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopropyl-6-
oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}-1
,2,4-oxadiazol-5(4H)-one (yield: 56%) as pale yellow
amorphous.
[0370]
155
1H-NMR(CDCl3, 400 MHz):
1.19(6H, d, J = 7 Hz), 1.24(3H, t, J = 8 Hz), 1.51(3H, t, J =
7 Hz), 2.28(1H, sept, J = 7 Hz), 2.69(2H, q, J = 8 Hz), 3.93(2H,
s), 4.22(2H, q, J = 7 Hz), 7.30(1H, d, J = 8 Hz), 7.37 - 7.41(2H,
m), 7.49(1H, dd, J = 8, 1 Hz), 7.67(1H, d, J = 8 Hz), 7.77(1H,
dd, J = 8, 2 Hz), 8.39(1H, d, J = 2 Hz), 8.51(2H, s).
[0371]
Example 45 Preparation of
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one
[0372]
[Chemical Formula 52]
[0373]
Process 1: By using cyclopropylcarbonyl chloride instead
of isobutyryl chloride in the Process 3 of the Example 40 and
also using methyl
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}penten
oate instead of methyl
156
(Z)-3-amino-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}hexeno
ate, the reaction was performed in the same manner as the Process
3 of the Example 40. According to a post-treatment carried out
in the same manner as the Process 3 of the Example 40, methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-cyclopropan
ecarboxamide-2-pentenoate (two step yield: 3.7%) was obtained
as a crude product.
[0374]
1H-NMR(CDCl3, 400 MHz):
0.85 - 0.90(2H, m), 1.05 - 1.08(3H, m), 1.16(3H, t, J = 8 Hz),
2.98(2H, q, J = 8 Hz), 3.72(3H, s), 3.77(2H, s), 7.49(1H, dd,
J = 8, 1 Hz), 7.59(1H, dd, J = 8, 2 Hz), 7.66 - 7.72(2H, m),
7.79(1H, d, J = 8 Hz), 7.83(1H, d, J = 8 Hz), 8.62(1H, d, J =
2 Hz), 12.1(1H, s).
[0375]
Process 2: By using methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-cyclopropan
ecarboxamide-2-pentenoate instead of methyl
(Z)-2-{[6-(2-cyanophenyl)pyridin-3-yl]methyl}-3-isobutylami
de-2-hexenoate in the Process 4 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 4 of the Example 40 to give
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le (yield: 13%).
[0376]
1H-NMR(CDCl3, 400 MHz):
157
0.82 - 0.88(2H, m), 1.08 - 1.15(1H, m), 1.18(3H, t, J = 8 Hz),
1.23 - 1.28(2H, m), 1.50(3H, t, J = 7 Hz), 2.63(2H, q, J = 8
Hz), 3.95(2H, s), 4.21(2H, q, J = 7 Hz), 7.44 - 7.48(1H, m),
7.64 - 7.66(2H, m), 7.76 - 7.78(3H, m), 8.53(2H, s), 8.7(1H,
d, J = 2 Hz).
[0377]
Process 3: By using
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitri
le instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}benzonitril
e in the Process 5 of the Example 40, the reaction and the
treatment were performed in the same manner as the Process 5
of the Example 40 to give
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide (yield: 52%).
[0378]
1H-NMR(CDCl3, 400 MHz):
0.82 - 0.88(2H, m), 1.04 - 1.12(1H, m), 1.15(3H, t, J = 8 Hz),
1.22 - 1.28(2H, m), 1.50(3H, t, J = 7 Hz), 2.62(2H, q, J = 8
Hz), 3.90(2H, s), 4.21(2H, q, J = 7 Hz), 4.76(2H, br), 7.38 -
7.40(2H, m), 7.47 - 7.51(2H, m), 7.57(1H, d, J = 8 Hz), 7.61(1H,
d, J = 8 Hz), 8.53(2H, s), 8.57(1H, s).
[0379]
Process 4: By using
158
2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-6-o
xo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydrox
ybenzimidamide instead of
2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propy
l-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}-N’-hydroxy
benzimidamide in the Process 6 of the Example 40, the reaction
and the treatment were performed in the same manner as the
Process 6 of the Example 40 to give
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-ethyl-
6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phenyl}
-1,2,4-oxadiazol-5(4H)-one (yield: 45%) as pale yellow
amorphous.
[0380]
1H-NMR(CDCl3, 400 MHz):
0.82 - 0.90(2H, m), 1.08 - 1.11(1H, m), 1.18(3H, t, J = 8 Hz),
1.23 - 1.26(2H, m), 1.51(3H, t, J = 7 Hz), 2.63(2H, q, J = 8
Hz), 3.91(2H, s), 4.21(2H, q, J = 7 Hz), 7.31(1H, d, J = 8 Hz),
7.37 - 7.44(2H, m), 7.51(1H, dd, J = 8, 2 Hz), 7.73(1H, d, J
= 8 Hz), 7.76(1H, dd, J = 8, 2 Hz), 8.40(1H, d, J = 2 Hz), 8.54(2H,
s).
[0381]
Test example 1: Angiotensin II antagonistic activity in
isolated rabbit blood vessels
By using a specimen of isolated rabbit blood vessels,
antagonistic activity of the compounds of the invention against
angiotensin II type 1 receptor was calculated from a
dose-response curve of angiotensin II-induced blood vessel
159
contraction. Specifically, the specimen of thoracic aorta
ring of a rabbit (New Zealand White: male, 2.4 to 3.0 kg) was
suspended in a magnus bath filled with Krebs-Henseleite buffer
(composition: 118 mM NaCl, 4.7 mM KCl, 2.55 mM CaCl2, 1.18 mM
MgSO4, 1.18 mM KH2PO4, 24.88 mM NaHCO3, and 11.1 mM D-glucose),
and angiotensin II (10 nM)-induced contraction was obtained in
the presence of each test compound (1 n mol/L to 10 mol/L).
During the measurement, the inside temperature of the magnus
bath was maintained at 37C and the bath was continuously
ventilated with a sufficient amount of mixed gas (95% O2 and
5% CO2). The angiotensin II-induced contraction was converted
into a relative value (%) that is based on the angiotensin II
(0.1 M)-induced contraction in the absence of the test
compound.
[0382]
As a result, it was confirmed that the compounds described
in the Examples have an angiotensin II antagonistic activity
at the concentration of 0.1 M. The inhibitory rate of
angiotensin II (10 nM) at the test compound concentration of
0.1 M is shown in the Table 1. As shown in the Table 1, it
was confirmed that the compounds of the invention have a potent
angiotensin II antagonistic activity, which is the same as
telmisartan. Meanwhile, under the same condition, rate of
inhibiting the angiotensin II activity by telmisartan was
85.3%.
[0383]
[Table 1]
160
[0384]
Test example 2: PPAR activation effect
The agonistic activity of the compounds of the invention
on PPAR was measured based on the transfection assay using COS7
cells (DS Pharma Biomedical Co., Ltd., Osaka, Japan), which are
the cell line derived from the kidney of the African green monkey.
COS7 cells were cultured under 5% CO2 concentration, and DMEM
medium containing 10% fetal bovine serum, glutamic acid, and
antibiotics was used as a medium.
As an expression vector, a chimera in which DNA binding
domain of Gal4, which is a yeast transcription factor, and
ligand binding domain of human PPAR2 are fused, i.e., a fused
161
product between the amino acids 1 to 147 of Gal4 transcription
factor and the amino acids 182 to 505 of human PPAR2, was used.
Furthermore, as a reporter vector, a firefly luciferase
containing five copies of Gal4 recognition sequence in the
promoter region was used. Plasmid transfection to the cells
was performed according to a method which uses jetPEI (trade
name, manufactured by Funakoshi Co., Ltd., Tokyo, Japan).
Furthermore, -galactosidase expression vector was employed as
an internal standard.
After the transfection into the cells, the medium was
replaced with a DMEM medium (containing 1% serum) added with
the test compound, and the cells were further cultured for 16
hours. After that, the luciferase activity and
-galactosidase activity in the cell lysis solution were
measured.
Meanwhile, for the present test, dimethylsulfoxide
(DMSO) was used for dissolution and dilution of the test
compounds, and during the cell treatment, the DMSO
concentration in DMEM medium (containing 1% serum) was adjusted
to 0.1%. As a positive compound, rosiglitazone (trade name,
manufactured by ALEXIS Corporation, Switzerland) was used.
The percentage (%) of the luciferase activity of the each test
compound (1 to 30 mol/L) was calculated when the luciferase
activity of rosiglitazone (3 to 10 mol/L) is 100% and the
luciferase activity in the absence of the test compound is 0%.
The 50% effective concentration of the test compound (EC50, 50%
effect concentration) was calculated by using SAS Preclinical
162
Package Ver 5.0 (trade name, manufactured by SAS institute Japan
Co., Tokyo, Japan), which is a statistical analysis program.
[0385]
As a result, it was confirmed that the compounds described
in the Examples have a PPAR activation effect at the
concentration of 30 M. The EC50 results are given in the Table
2. As shown in the Table 2, it was confirmed that the compounds
of the invention have a potent PPAR activation effect. In
particular, several compounds in the Table 2 exhibited EC50 value
of less than 1 M, indicating stronger PPAR activation effect
than telmisartan. Maximum activity strength of several
compounds relative to the maximum activity of rosiglitazone is
given in the Table 3. As shown in Table 3, it was confirmed
that the compounds of the invention have an activity that is
20 to 69% of the maximum activity of rosiglitazone and they have
a sufficient agonist activity on PPAR. In particular, the
maximum activity of the compounds of the Examples 40, 41, 42,
and 43 was 42 to 69%, which is the same or greater than that
of telmisartan. Under the same condition, the PPAR activation
effect of telmisartan, i.e., EC50, was 1 to 5 M, and the maximum
activity strength of telmisartan relative to the maximum
activity of rosiglitazone (i.e., % MAX vs. rosiglitazone) was
30 to 50%.
[0386]
[Table 2]
163
[0387]
[Table 3]
[0388]
From the results obtained above, it was confirmed that
the compounds of the present invention have both a potent
angiotensin II receptor antagonistic activity and a PPAR
164
activation effect. Thus, it was found that the compounds of
the present invention and pharmaceutically acceptable salts
thereof are useful as an effective component of a prophylactic
and/or therapeutic agent for disorders involved with
angiotensin II and PPAR, for example, hypertension, heart
diseases, angina pectoris, cerebral vascular disorders,
cerebral circulatory disorders, ischemic peripheral
circulatory disorders, renal diseases, arteriosclerosis,
inflammatory diseases, type 2 diabetes, diabetic complications,
insulin resistance syndrome, syndrome X, metabolic syndrome,
and hyperinsulinemia.
INDUSTRIAL APPLICABILITY
[0389]
The phenylpyridine derivatives represented by the
formula (I) of the invention or salts thereof, or solvates
thereof are a novel compound which have both an angiotensin II
receptor antagonistic activity and a PPAR activation effect,
and the present invention provides the novel compounds and a
pharmaceutical composition containing the same. The compounds
of the invention are used as an effective component of a novel
pharmaceutical product, i.e., a prophylactic and/or
therapeutic agent for disorders involved with angiotensin II
and PPAR, for example, hypertension, heart diseases, angina
pectoris, cerebral vascular disorders, cerebral circulatory
disorders, ischemic peripheral circulatory disorders, renal
diseases, arteriosclerosis, inflammatory diseases, type 2
165
diabetes, diabetic complications, insulin resistance syndrome,
syndrome X, metabolic syndrome, and hyperinsulinemia, and
therefore have an industrial applicability.
166
We Claim:-
1. A compound represented by the formula (I) below or a salt
thereof, or a solvate thereof:
[Chemical Formula 1]
[in the formula, ring A represents the following formula
(II) or formula (III):
[Chemical Formula 2]
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 3]
167
X represents C-R5 or a nitrogen atom,
R1 represents a C1-3 alkyl group or a C5-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
2. The compound according to Claim 1 or a salt thereof, or
a solvate thereof, wherein the ring A in the formula (I) is the
formula (II) and the ring B is the formula (V).
3. The compound according to Claim 1 or 2 or a salt thereof,
or a solvate thereof, wherein X in the formula (I) is a nitrogen
atom and R3 and R4 are each independently a hydrogen atom, a
halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or a
C1-6 alkoxy group.
4. The compound according to Claim 3 or a salt thereof, or
a solvate thereof, wherein R3 and R4 in the formula (I) are each
168
independently a hydrogen atom or a C1-6 alkoxy group.
5. The compound according to any one of Claims 1 to 4 or a
salt thereof, or a solvate thereof, wherein the compound
represented by the formula (I) is a compound selected from a
group consisting of:
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-ox
o-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}ph
enyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-
oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}
phenyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-ox
o-4-pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}ph
enyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-
oxo-4-pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}
phenyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopro
pyl-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phe
nyl}-1,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-
ethyl-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}p
henyl}-1,2,4-oxadiazol-5(4H)-one.
6. A pharmaceutical composition containing a compound
represented by the formula (I) below or a salt thereof, or a
169
solvate thereof, and a pharmaceutically acceptable carrier:
[Chemical Formula 4]
[in the formula, ring A represents the following formula
(II) or formula (III):
[Chemical Formula 5]
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 6]
170
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
7. The pharmaceutical composition according to Claim 6,
wherein R1 in the formula (I) is a C1-3 alkyl group or a C5-6 alkyl
group.
8. The pharmaceutical composition according to Claim 6 or
7, wherein the ring A in the formula (I) is the formula (II)
and the ring B is the formula (V).
9. The pharmaceutical composition according to any one of
Claims 6 to 8, wherein X in the formula (I) is a nitrogen atom
and R3 and R4 are each independently a hydrogen atom, a halogen
171
atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or a C1-6 alkoxy
group.
10. The pharmaceutical composition according to Claim 9,
wherein R3 and R4 in the formula (I) are each independently a
hydrogen atom or a C1-6 alkoxy group.
11. The pharmaceutical composition according to any one of
Claims 6 to 10, wherein the compound represented by the formula
(I) is a compound selected from a group consisting of:
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-ox
o-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}ph
enyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-
oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}
phenyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-ox
o-4-pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}ph
enyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-6-
oxo-4-pentyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}
phenyl}-1,2,4-oxadiazol-5(4H)-one,
3-{2-{5-{[1-(5-ethoxypyrimidin-2-yl)-4-ethyl-2-isopro
pyl-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}phe
nyl}-1,2,4-oxadiazol-5(4H)-one, and
3-{2-{5-{[2-cyclopropyl-1-(5-ethoxypyrimidin-2-yl)-4-
ethyl-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl}p
172
henyl}-1,2,4-oxadiazol-5(4H)-one.
12. The pharmaceutical composition according to any one of
Claims 6 to 11, having both angiotensin II receptor antagonistic
activity and a PPAR activation effect.
13. The pharmaceutical composition according to any one of
Claims 6 to 11, which is an agent for preventing and/or treating
a circulatory disease.
14. The pharmaceutical composition according to Claim 13,
wherein the circulatory disease is hypertension, heart disease,
angina pectoris, cerebral vascular disorder, cerebral
circulatory disorder, ischemic peripheral circulatory
disorder, kidney disease, or arteriosclerosis.
15. The pharmaceutical composition according to any one of
Claims 6 to 11, which is an agent for preventing and/or treating
a metabolic disease.
16. The pharmaceutical composition according to Claim 15,
wherein the metabolic disease is type 2 diabetes mellitus,
diabetic complication (diabetic retinopathy, diabetic
neuropathy, or diabetic nephropathy), insulin resistant
syndrome, metabolic syndrome, or hyperinsulinemia.
17. A method of preventing and/or treating a circulatory
173
disease, the method comprising administering an effective
amount of the compound represented by the following formula (I)
or a salt thereof, or a solvate thereof to a patient who is in
need of the treatment:
[Chemical Formula 7]
[in the formula, ring A represents the following formula
(II) or formula (III):
[Chemical Formula 8]
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 9]
174
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
18. A method of preventing and/or treating a metabolic
disease, the method comprising administering an effective
amount of the compound represented by the following formula (I)
or a salt thereof, or a solvate thereof to a patient who is in
need of the treatment:
[Chemical Formula 10]
175
[in the formula, ring A represents the following formula
(II) or formula (III):
[Chemical Formula 11]
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 12]
176
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
19. A method of preventing and/or treating a circulatory
disease and a metabolic disease, the method comprising
administering an effective amount of the compound represented
by the following formula (I) or a salt thereof, or a solvate
thereof to a patient who is in need of the treatment:
[Chemical Formula 13]
[in the formula, ring A represents the following formula
177
(II) or formula (III):
[Chemical Formula 14]
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 15]
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
20. A compound represented by the following formula (I) or
178
a salt thereof, or a solvate thereof to be used for preventing
and/or treating a circulatory disease:
[Chemical Formula 16]
[in the formula, ring A represents the following formula
(II) or formula (III):
[Chemical Formula 17]
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 18]
179
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
21. A compound represented by the following formula (I) or
a salt thereof, or a solvate thereof to be used for preventing
and/or treating a metabolic disease:
[Chemical Formula 19]
180
[in the formula, ring A represents the following formula
(II) or formula (III):
[Chemical Formula 20]
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 21]
181
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].
22. A compound represented by the following formula (I) or
a salt thereof, or a solvate thereof to be used for preventing
and/or treating a circulatory disease and a metabolic disease:
[Chemical Formula 22]
[in the formula, ring A represents the following formula
(II) or formula (III):
[Chemical Formula 23]
182
ring B represents the following formula (IV) or formula
(V):
[Chemical Formula 24]
X represents C-R5 or a nitrogen atom,
R1 represents a C1-6 alkyl group,
R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group,
and
R3, R4, and R5 each independently represent a hydrogen atom,
a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, or
a C1-6 alkoxy group which may have a substituent group, and the
broken line in the formula indicates the binding site for a
neighboring group].